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Perk Genetic Variation and Function in Progressive Supranuclear Palsy
Abstract
Progressive supranuclear palsy (PSP) is a neurodegenerative disorder pathologically characterized by
intracellular tangles of hyperphosphorylated tau protein distributed throughout the neocortex, basal
ganglia, and brainstem. A genome-wide association study identified EIF2AK3 as a risk factor for PSP.
EIF2AK3 encodes PERK, part of the endoplasmic reticulum’s (ER) unfolded protein response (UPR). PERK
is an ER membrane protein that senses unfolded protein accumulation within the ER lumen. Recently,
several groups noted UPR activation in Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic
lateral sclerosis, multiple system atrophy, and in the hippocampus and substantia nigra of PSP subjects.
In Chapter 2, we evaluate PERK activation in the pons, medulla, midbrain, hippocampus, frontal cortex and
cerebellum in subjects with PSP, AD, and in normal controls. We found UPR activation primarily in diseaseaffected brain regions in both disorders. In PSP, the UPR was primarily activated in the pons and medulla
and to a much lesser extent in the hippocampus. In AD, the UPR was extensively activated in the
hippocampus. We also observed UPR activation in the hippocampus of some elderly normal controls,
severity of which positively correlated with both age and tau pathology but not with Aβ plaque burden.
Finally, we evaluated EIF2AK3 coding variants that influence PERK activation. We show that a PERK
haplotype that demonstrates increased eIF2α kinase activity is genetically associated with increased PSP
risk. The UPR is activated in disease affected regions in PSP and the genetic and biological evidence
shows that this activation increases risk for PSP and is not a protective response.
There are two common protein coding variants of PERK, HapA and HapB, which differ by three amino
acids. Recent work indicates HapB PERK has more kinase activity in response to thapsigargin treatment
than does HapA in human β-lymphocytes. The goal of the work detailed in Chapter 3 was to: 1) replicate
and expand upon previous findings in β-lymphocytes and 2) determine which of the three amino acid
coding changes is responsible for the difference in PERK activity between HapA and HapB. This work
confirms that β-lymphocytes expressing HapB PERK show more eIF2α phosphorylation than those
expressing HapA. Paradoxically, HapB PERK cells also show less phosphorylated PERK. These findings
were echoed in mouse embryonic fibroblasts expressing PERK variant constructs. Further work exploring
the functional differences between PERK variants is warranted.
Chapter 4 discusses the implications of the work detailed in Chapters 2 and 3 and suggests future
directions for this work, including examination of post-translational modifications of PERK and
exploration of how PERK variants function in cell culture models of tauopathy.
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ABSTRACT
PERK GENETIC VARIATION AND FUNCTION IN PROGRESSIVE SUPRANUCLEAR
PALSY
Lauren Denise Stutzbach
Gerard D. Schellenberg
Progressive supranuclear palsy (PSP) is a neurodegenerative disorder pathologically
characterized by intracellular tangles of hyperphosphorylated tau protein distributed
throughout the neocortex, basal ganglia, and brainstem. A genome-wide association
study identified EIF2AK3 as a risk factor for PSP. EIF2AK3 encodes PERK, part of the
endoplasmic reticulum’s (ER) unfolded protein response (UPR). PERK is an ER
membrane protein that senses unfolded protein accumulation within the ER lumen.
Recently, several groups noted UPR activation in Alzheimer’s disease (AD), Parkinson’s
disease (PD), amyotrophic lateral sclerosis, multiple system atrophy, and in the
hippocampus and substantia nigra of PSP subjects. In Chapter 2, we evaluate PERK
activation in the pons, medulla, midbrain, hippocampus, frontal cortex and cerebellum in
subjects with PSP, AD, and in normal controls. We found UPR activation primarily in
disease-affected brain regions in both disorders. In PSP, the UPR was primarily
activated in the pons and medulla and to a much lesser extent in the hippocampus. In
AD, the UPR was extensively activated in the hippocampus. We also observed UPR
activation in the hippocampus of some elderly normal controls, severity of which
positively correlated with both age and tau pathology but not with Aβ plaque burden.
vi

Finally, we evaluated EIF2AK3 coding variants that influence PERK activation. We
show that a PERK haplotype that demonstrates increased eIF2α kinase activity is
genetically associated with increased PSP risk. The UPR is activated in disease
affected regions in PSP and the genetic and biological evidence shows that this
activation increases risk for PSP and is not a protective response.
There are two common protein coding variants of PERK, HapA and HapB, which differ
by three amino acids. Recent work indicates HapB PERK has more kinase activity in
response to thapsigargin treatment than does HapA in human β-lymphocytes. The goal
of the work detailed in Chapter 3 was to: 1) replicate and expand upon previous findings
in β-lymphocytes and 2) determine which of the three amino acid coding changes is
responsible for the difference in PERK activity between HapA and HapB. This work
confirms that β-lymphocytes expressing HapB PERK show more eIF2α phosphorylation
than those expressing HapA. Paradoxically, HapB PERK cells also show less
phosphorylated PERK. These findings were echoed in mouse embryonic fibroblasts
expressing PERK variant constructs. Further work exploring the functional differences
between PERK variants is warranted.
Chapter 4 discusses the implications of the work detailed in Chapters 2 and 3 and
suggests future directions for this work, including examination of post-translational
modifications of PERK and exploration of how PERK variants function in cell culture
models of tauopathy.
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CHAPTER 1: INTRODUCTION

Progressive Supranuclear Palsy (PSP)
PSP is a devastating neurodegenerative disease that presents with gaze palsy,
gait disturbance, difficulty swallowing and speaking, and dementia (Steele, Richardson,
& Olszewski, 1964). Patient prognosis is usually poor, and affected individuals can
expect to survive only a few years from initial diagnosis (dell’Aquila et al., 2013). There
are currently no drug or surgical treatments that prevent disease onset or progression,
and symptomatic treatment for PSP has minimal, sustained clinical efficacy (Bensimon
et al., 2009; Chang & Weirich, 2014; Cotter, Armytage, & Crimmins, 2010; Frattali,
Sonies, Chi-Fishman, & Litvan, 1999; Golbe, 2014). Thus, it is critical to identify drug
targets for this disease to reduce the suffering of patients and their families.
PSP is part of a group of neurodegenerative diseases known as tauopathies,
diseases characterized by intracellular aggregates of the protein tau in affected brain
regions. Other diseases in this group include Alzheimer’s disease (AD), corticobasal
degeneration (CBD), Pick’s disease, and some forms of frontotemporal dementia (FTD)
(Kovacs, 2014). Though all of these diseases demonstrate similar tau pathology, the
location of that pathology in the brain varies with each disorder’s symptomatic
presentation. For example, tau aggregates are most abundant in the frontal and
temporal cortex of patients with FTD, and these patients present with difficulty in
executive functioning and/or language processing (behavioral-variant FTD and primary
progressive aphasia, respectively). Tau aggregates in PSP are primarily in the
brainstem, the location of many nuclei that control eye movement, balance, and tongue
and throat movements, and in the basal ganglia, the brain’s general movement control
center (Dickson, Kouri, Murray, & Josephs, 2011; Hauw et al., 1994; Irwin et al., 2014).
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However, tauopathies present with a spectrum of pathology and clinical symptoms, and
there is considerable overlap between them (Irwin et al., 2014; Kobylecki et al., 2015).
This complicates diagnosis both pre- and postmortem, but also allows research into
specific tauopathies to inform research about this class of neurodegenerative disorders
in general. Thus, though PSP is relatively rare (Steele et al., 1964), investigation into its
pathogenesis may be more widely applicable.
PSP tau pathology at its least severe appears in the subthalamic nucleus,
substantia nigra, and globus pallidus. As pathological severity increases, tau pathology
appears progressively in the posterior frontal lobe, dentate nucleus, pons, caudate and
anterior frontal and parietal lobes. The more brain regions tau affects the shorter the
duration of the disease. Sub classifications of PSP, including the classical Richardson’s
syndrome (RS), PSP-parkinsonism (PSP-P), and pure akinesia with gait freezing
(PAGF) present with distinct pathological footprints in the brain, with the highest severity
of tau pathology evident in RS and the lowest in PSP-P (Williams et al., 2007). The
prognosis for RS is also significantly worse than for PSP-P (dell’Aquila et al., 2013).
Thus, both distribution and severity of tau pathology dictate clinical presentation and
disease duration.

Tau function and dysfunction in neurodegenerative disease
Microtubule-associated binding protein tau (MAPT) binds to tubulin and helps
stabilize and facilitate assembly of microtubules (Hirokawa, 1994), regulate intracellular
organelle transport and the attachment of motor proteins to tubulin (Ebneth et al., 1998;
Sato-Harada, Okabe, Umeyama, Kanai, & Hirokawa, 1996; Trinczek, Ebneth,
Mandelkow, & Mandelkow, 1999), and influence the structure of the neuron (reviewed in
Shahani and Brandt 2002). Deletion of the MAPT gene produces relatively subtle
2

phenotypes in mouse models, suggesting some functional redundancy between tau and
other MAPs (Dawson et al., 2001; Harada et al., 1994). In the brain, tau is abundantly
expressed in axons (Binder, Frankfurter, & Rebhun, 1985), while expression in glial cells
is more moderate (LoPresti, Szuchet, Papasozomenos, Zinkowski, & Binder, 1995). It is
unclear whether tau’s prominence as a pathological feature of so many
neurodegenerative diseases is a result of a loss of function, a gain of toxic function, or
some combination of the two (Shahani & Brandt, 2002).
Though it is a natively unfolded protein, many post-translational modifications
(PTMs) can affect tau’s conformation and function. Many of these modifications,
especially phosphorylation, also serve as signposts of tau pathology (Iqbal, Liu, Gong,
Alonso, & Grundke-Iqbal, 2009; Noble, Hanger, Miller, & Lovestone, 2013). Before it
forms tangles, tau becomes “hyperphosphorylated” (Bancher et al., 1989) and thus more
likely to aggregate. Though mature neurofibrillary tangles (NFTs) have long been
recognized as the pathological hallmarks of tauopathy, it may be that these aggregates
act as therapeutic sinks for hyperphosphorylated tau (htau). In this model, it is small
accumulations of oligomeric htau that promote neurodegeneration, not NFTs (Brunden,
Trojanowski, & Lee, 2008; Gerson et al., 2014; Iqbal et al., 2009).
Recent work supports the hypothesis that abnormal tau can move from one cell
to an adjacent cell and “seed” new tau aggregation. The seeds potentially initiate
aggregate formation by acting through a prion-like mechanism, recruiting soluble tau into
the tangle seed (Clavaguera et al., 2009; Goedert, Clavaguera, & Tolnay, 2010; Guo &
Lee, 2011; Sanders et al., 2014). This theory is supported by the observation that brain
homogenates from various tauopathies can induce tangle formation when they are
injected into mouse brain (Clavaguera et al., 2013). In AD, the cell non-autonomous
model is consistent with the widely accepted hypothesis that tau pathology initiates in
3

the entorhinal cortex, and then spreads to the hippocampus and neocortex (Braak et al.
2006; Braak and Braak 1991). This non-autonomous mechanism may also occur in
PSP, in which tau pathology initiates in the brainstem.

Genetics of PSP
There is considerable phenotypic variability in the clinical presentation of PSP
(Respondek et al., 2014), and efforts to treat it could be hindered by the difficulty of early
diagnosis. As with many neurodegenerative diseases, the symptoms that prompt a
patient to seek diagnosis and treatment may come too late for effective intervention,
even once such interventions are available. Thus, it will be imperative, moving forward,
to identify not only the earliest symptoms of disease, but also to screen people
prospectively for risk factors. This screening could be both physiological, as in biomarker
analysis, and genetic.
Some mutations in the gene MAPT, which codes for tau, result in a PSP
phenotype (Poorkaj et al., 2002; Rademakers et al., 2005; Stanford et al., 2000), further
establishing tau’s role as a crucial player in PSP pathogenesis. A common inversion
haplotype in MAPT also increases risk for developing PSP (Baker et al., 1999). This
haplotype, called H1, represents an inversion of several genes in the vicinity of MAPT on
chromosome 17, including Saitohin, NSF, IMP5, CRHR1, and LOC284058 (Pittman,
2005; Stefansson et al., 2005). The alternative haplotype, H2, is present almost
exclusively in Europeans and may be protective against PSP (Pau Pastor et al., 2004).
Further work is needed to determine why H1 confers PSP risk, though the likely origin is
MAPT itself (Pittman, 2005).
Alternative splicing of exons 2, 3, and 10 of MAPT result in six different tau
isoforms, each containing either one or two acidic inserts at the N-terminal end of tau
4

and three or four microtubule (MT) binding repeats near the C-terminal end of tau (3R
tau and 4R tau; Gendron and Petrucelli 2009). The difference in number of MT binding
repeats affects binding affinity; these tau isoforms compete for the same MT binding
sites, and 4R tau can displace MT-bound 3R tau (M. Lu & Kosik, 2001). Pathological tau
aggregates in PSP are composed only of 4R tau, whereas similar aggregates in Pick’s
disease are composed of 3R tau (Buee & Delacourte, 1999). NFTs in AD are a mix of
3R and 4R tau (Togo et al., 2004). This indicates genetic variants influencing tau
expression and splicing may be critical in determining an individual’s risk of developing a
particular tauopathy (Pittman, 2005).
Schellenberg and colleagues recently completed a genome-wide association
screen (GWAS) for additional PSP risk loci (Höglinger et al., 2011). GWASs compare
common single nucleotide polymorphisms (SNPs) between affected and unaffected
individuals for a particular disease or trait. “Hit” SNPs act as signposts indicating a riskconferring genetic feature is nearby, and the actual risk locus is likely in strong linkage
disequilibrium (LD) with that hit SNP. The PSP GWAS identified several genes that
contribute to PSP risk, including STX6 (encoding syntaxin 6), MOBP (encoding myelinassociated oligodendrocyte basic protein), and EIF2AK3 (encoding eukaryotic
translation initiation factor 2 alpha kinase 3, also called PERK). PERK is an ER
membrane protein that acts as a stress sensor in the ER unfolded protein response
(UPR).

PERK and the Unfolded Protein Response (UPR)
In addition to PERK, there are two other UPR stress sensors (both of which are
also ER membrane proteins): inositol-requiring enzyme 1α (IRE1α) and activating
transcription factor 6 (ATF6; Ron and Walter 2007). All arms of the UPR activate when
5

the chaperone BiP, normally bound on the luminal side of each protein, dissociates in
order to aid in the re-folding of accumulated misfolded proteins in the ER lumen. This
facilitates translocation and cleavage of ATF6 and exposes a phosphorylation site on
both PERK and IRE1α (Scheper & Hoozemans, 2009). Each of the three branches of
the UPR initiates discrete signaling cascades in response to the accumulation of mis- or
unfolded proteins in the ER lumen. These signaling cascades can be both protective and
destructive to the cell. Though the protective role of the UPR is to restore homeostasis
by attenuating translation, promoting ER-associated degradation (ERAD; Travers et al.
2000), and upregulating chaperone production (Kozutsumi, Segal, Normington, Gething,
& Sambrook, 1988; Matus, Glimcher, & Hetz, 2011), prolonged ER stress can trigger
apoptosis (Rutkowski et al., 2006; Urra, Dufey, Lisbona, Rojas-Rivera, & Hetz, 2013).
The PERK arm of the UPR acts primarily on translation. When PERK is activated
(thus becoming phosphorylated PERK, or pPERK), a kinase domain on the cytosolic
side of the protein phosphorylates eukaryotic translation initiation factor 2α (eIF2α).
peIF2α then acts at the ribosome to slow down general translation initiation and promote
translation of ATF4. ATF4 promotes the transcription of genes that enhance import of
amino acids and protect against oxidative stress (Harding et al., 2003). However, ATF4
also increases expression of CHOP, a transcription factor that promotes both
dephosphorylation of eIF2α (via the phosphatase GADD34) and apoptosis (Tabas &
Ron, 2011).
Elements of the PERK pathway are also involved in another important cellular
response to misfolded protein accumulation: autophagy (Rouschop et al., 2010;
Yorimitsu, Nair, Yang, & Klionsky, 2006). UPR activation induces formation of
autophagosome-like structures that engulf portions of the ER itself, potentially acting as
a negative regulator of ER expansion during stress (Bernales, McDonald, & Walter,
6

2006). More specifically, PERK activation significantly upregulates transcription of
autophagy receptor genes (Deegan et al., 2015). This upregulation of autophagy in
response to ER stress may help restore normal cell functioning and promote cell survival
(Ogata et al., 2006).
Genetic variation that either alters the PERK protein or regulates the amount of
this protein in the cell could perturb these crucial stress-response pathways and
contribute to disease pathogenesis or progression in PSP and other neurodegenerative
diseases. A developing body of literature supports PERK’s role as an important player in
neurodegeneration and suggests that further study of PERK genetics and protein
function could yield important insights into potential treatment options for these diseases
(Hetz & Mollereau, 2014).

The function and dysfunction of the UPR in disease
Previous work showed that the UPR is activated in post-mortem brains from AD
(Jeroen J M Hoozemans et al., 2009), Parkinson’s disease (J J M Hoozemans et al.,
2007), amyotrophic lateral sclerosis (Atkin et al., 2008; Wang, Popko, & Roos, 2010),
frontotemporal dementia (D. A. T. Nijholt, van Haastert, Rozemuller, Scheper, &
Hoozemans, 2012) and multiple system atrophy (Makioka et al., 2010) patients. The
UPR is also activated in PSP (Stutzbach et al., 2013, see Chapter 2) All of these
disorders, PSP included, are characterized by pathological aggregates of misfolded
proteins in the brain. The UPR tends to be activated in cells with early-stage staining for
neuropathological proteins (usually a diffuse staining pattern) rather than full-blown
tangles or inclusions, suggesting that activation of the UPR is an early event in disease
(Jeroen J M Hoozemans et al., 2009; Makioka et al., 2010; D. A. T. Nijholt et al., 2012).
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Activation of the UPR generally and PERK specifically could influence
neurodegeneration in several ways. First, it is important to note that tau aggregates are
primarily cytoplasmic and do not generally traffic through the ER (Congdon & Duff,
2008). This means that misfolded tau is not directly triggering the UPR via accumulation
in the ER lumen. However, large protein aggregates or small, toxic accumulations of
htau oligomers could interfere with cytoplasmic components of the UPR signaling
machinery, particularly endoplasmic reticulum-associated degradation (ERAD) and
autophagy. A “backlog” of cytoplasmic proteins targeted for degradation could interfere
with the normal degradation of misfolded proteins exported from the ER and could
impede upregulation of protein degradation (Abisambra et al., 2013). This downstream
roadblock could initiate prolonged ER stress and bias the cell toward apoptosis (Urra et
al., 2013).
Another way PERK activity may influence neurodegeneration is via translational
inhibition. Though this global decrease in protein translation may be helpful in the short
term, prolonged lack of protein synthesis is ultimately detrimental. Work from Moreno et
al. (2012) showed that prion infected mice demonstrated prolonged phosphorylation of
eIF2α along with synaptic deficits and neurodegeneration. However, overexpression of
GADD34, an eIF2α phosphatase (Ron & Walter, 2007), restored translation and rescued
several prion disease phenotypes, increasing survival. Conversely, treatment with
salubrinal, an inhibitor of eIF2α phosphatases (Boyce et al., 2005), exacerbated neuron
loss and decreased survival. This could indicate that translational repression mediated
by sustained eIF2α phosphorylation interferes with normal neuronal function and may
bias the cell toward degeneration.
Though moderate PERK depletion might prove beneficial in the case of
neurodegeneration, complete loss of PERK could be detrimental. The developmental
8

disorder Wolcott-Rallison syndrome results from PERK insufficiency (Delépine et al.,
2000). Wolcott-Rollin presents with skeletal dysplasia, growth retardation, and diabetes
mellitus (Stöss, Pesch, Pontz, Otten, & Spranger, 1982). PERK knockout in a mouse
model results in a similar phenotype (Peichuan Zhang et al., 2002). Thus, any treatment
targeting PERK would need to modulate rather than eliminate its activity. Indeed, a
follow-up study from Moreno et al.(2013) showed that though treatment with a selective
PERK inhibitor rescued several disease phenotypes in prion-infected mice, it also
increased glucose levels and resulted in a 20% decrease in body weight.
Phosphorylation of eIF2α also plays a role in synaptic plasticity and memory
(Hetz & Mollereau, 2014). Conditional PERK knockout in an APP-PS1 mouse line
rescues Aβ-related defects in spatial memory and long-term potentiation (LTP; Ma et al.
2013). The effect is similar for knockout of GCN2, another eIF2α kinase. Without the de
novo protein synthesis that is largely blocked by prolonged eIF2α phosphorylation,
memory formation and consolidation are severely impaired. Thus, stress conditions in
the cell that continuously trigger eIF2α kinases like PERK and GCN2 may be partially
responsible for memory-related symptoms of neurodegeneration. Likewise, any
alterations to PERK that increase its eIF2α kinase activity could directly contribute to
neurodegenerative disease pathogenesis or progression.
Recent work from Liu et al. (2012) demonstrated that there are two common
PERK coding haplotypes, designated Haplotype A (HapA; more common) and
Haplotype B (HapB; less common). In human β-lymphocytes, cells homozygously
expressing HapB demonstrated significantly more eIF2α phosphorylation in response to
treatment with the ER stress-inducing drug thapsigargin (Rogers, Inesi, Wade, &
Lederer, 1995) than did cells expressing HapA. Interestingly, the three SNPs that confer
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the coding differences between HapA and HapB are in strong LD with the PSP GWAS
SNP giving the strongest signal in the PERK gene (Höglinger et al., 2011; Stutzbach et
al., 2013). This presents a potential pathogenic mechanism for PERK’s involvement in
PSP and is the focus of this thesis.

Novel questions addressed by this thesis

Is PERK activated in disease-affected brain regions in PSP?
There is evidence of UPR activation in Alzheimer’s disease (AD), Parkinson’s
disease (PD), amyotrophic lateral sclerosis, multiple system atrophy, and in the
hippocampus and substantia nigra of PSP subjects (Atkin et al., 2008; J J M Hoozemans
et al., 2007; Jeroen J M Hoozemans et al., 2009; Makioka et al., 2010; D. A. T. Nijholt et
al., 2012; Wang et al., 2010). In Chapter 2 of this thesis, I evaluate PERK activation in
the pons, medulla, midbrain, hippocampus, frontal cortex and cerebellum in subjects
with PSP, AD, and in normal controls. UPR activation may be an early event in
neurodegenerative pathogenesis (Jeroen J M Hoozemans et al., 2009). Therefore, I also
determine whether this activation co-localizes with pre-tangle tau pathology, both in
disease and normal controls.

Are PERK variants associated with PSP?
Schellenberg and colleagues recently completed a genome-wide association
screen (GWAS) for PSP risk loci (Höglinger et al., 2011). One of the genes identified
was eukaryotic translation initiation factor 2 alpha kinase 3 (EIF2AK3 or PERK). The
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SNP identified in the PSP GWAS is in strong LD with two common PERK haplotypes
that differ at three amino acids: S136-R166-A704 (low risk allele, called HapA) or C136Q166-S704 (higher risk allele, called HapB). In the second part of Chapter 2, I examine
whether these PERK coding haplotypes are associated with PSP risk.

How do variations in the PERK protein affect activity?
These coding changes are potentially functional variants of PERK and may affect
its role in the UPR. Work from Liu et al. (2012) showed that HapB PERK has a stronger
response to drug-induced ER stress than HapA PERK. Also, at least one of the three
coding changes, S136C (rs867529), is predicted by several methods to be a deleterious
substitution for PERK (Burke et al., 2007). Thus, the goal of the second part of my
thesis is to replicate the findings of Liu et al. (2012) and to determine which of the three
amino acid variations that comprise the PERK haplotypes are responsible for this
functional difference. To do this, I first examine phosphorylation of PERK and eIF2α in
human β-lymphocytes. I then express artificial PERK variant constructs with single
amino acid alterations in mouse embryonic fibroblasts (MEFs) derived from PERK null
mice and assess phosphorylation of PERK and eIF2α as well as ATF4.
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ABSTRACT
Background: Progressive supranuclear palsy (PSP) is a neurodegenerative disorder
pathologically characterized by intracellular tangles of hyperphosphorylated tau protein
distributed throughout the neocortex, basal ganglia, and brainstem. A genome-wide
association study identified EIF2AK3 as a risk factor for PSP. EIF2AK3 encodes PERK,
part of the endoplasmic reticulum’s (ER) unfolded protein response (UPR). PERK is an
ER membrane protein that senses unfolded protein accumulation within the ER lumen.
Recently, several groups noted UPR activation in Alzheimer’s disease (AD), Parkinson’s
disease (PD), amyotrophic lateral sclerosis, multiple system atrophy, and in the
hippocampus and substantia nigra of PSP subjects. Here, we evaluate UPR PERK
activation in the pons, medulla, midbrain, hippocampus, frontal cortex and cerebellum in
subjects with PSP, AD, and in normal controls. Results: We found UPR activation
primarily in disease-affected brain regions in both disorders. In PSP, the UPR was
primarily activated in the pons and medulla and to a much lesser extent in the
hippocampus. In AD, the UPR was extensively activated in the hippocampus. We also
observed UPR activation in the hippocampus of some elderly normal controls, severity of
which positively correlated with both age and tau pathology but not with Aβ plaque
burden. Finally, we evaluated EIF2AK3 coding variants that influence PERK activation.
We show that a haplotype associated with increased PERK activation is genetically
associated with increased PSP risk. Conclusions: The UPR is activated in disease
affected regions in PSP and the genetic evidence shows that this activation increases
risk for PSP and is not a protective response.
Keywords:

Progressive supranuclear palsy; PERK; Unfolded protein response;
EIF2AK3; Alzheimer’s disease
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INTRODUCTION
Progressive supranuclear palsy (PSP) is a late-onset neurodegenerative movement
disorder clinically characterized by vertical gaze palsy, poor balance and frequent falls,
as well as cognitive impairment and dementia (Litvan, 1998; Steele et al., 1964). The
primary symptoms of PSP are consistent with the observed neuropathology, mainly
neuronal degeneration in the brainstem, particularly the pons and medulla (Dickson,
Rademakers, & Hutton, 2007). Postmortem pathological analysis of these brain regions
in PSP patients reveals numerous intracellular neurofibrillary and glial tangles comprised
of hyperphosphorylated protein tau (htau). Thus PSP, along with Alzheimer’s disease
(AD), belongs to a group of disorders collectively known as tauopathies, as all these
disorders show abundant tau aggregates or inclusions as prominent neuropathologic
features. Other tauopathies include frontotemporal dementia with parkinsonism linked to
chromosome 17 (FTDP-17), corticobasal degeneration (CBD), and Pick’s disease
(Ballatore, Lee, & Trojanowski, 2007). Some mutations in the gene MAPT, which
encodes tau, can result in a PSP phenotype (P Pastor et al., 2001; Poorkaj et al., 2002;
Ros et al., 2005; Rossi et al., 2004; Stanford et al., 2000), while common variants in the
MAPT region are associated with PSP susceptibility (Baker et al., 1999; Conrad et al.,
1997; Cruchaga et al., 2009; Höglinger et al., 2011). Thus, genetic studies as well as our
data here indicate that tau is clearly linked to PSP pathogenesis.
Schellenberg and colleagues recently completed a genome-wide association study
(GWAS) for PSP risk loci (Höglinger et al., 2011). One of the genes identified was
eukaryotic translation initiation factor 2 alpha kinase 3 (EIF2AK3), which encodes the
protein pancreatic endoplasmic reticulum kinase (PERK). PERK is an endoplasmic
reticulum (ER) membrane protein that acts as a stress sensor in the ER unfolded protein
response (UPR). In addition to PERK, there are two other stress sensors (both of which
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are also ER membrane proteins): inositol-requiring enzyme 1α (IRE1α) and activating
transcription factor 6 (ATF6; Ron & Walter, 2007).
All three arms of the UPR activate when the chaperone immunoglobulin binding
protein (BiP), normally bound on the luminal side of each protein, dissociates in order to
aid in the folding of accumulated unfolded proteins in the ER lumen. Dissociation of BiP
from PERK and IRE1α facilitates their activation by promoting homodimerization and
trans-autophosphorylation (Walter & Ron, 2011). ATF6 is then activated via a cleavage
event and subsequently translocated from the ER to the nucleus (Scheper &
Hoozemans, 2009). Each of the three branches of the UPR initiates discrete signaling
cascades in response to the accumulation of unfolded proteins in the ER lumen. The
role of the UPR is to restore protein homeostasis by upregulating chaperone production
(Kozutsumi et al., 1988; Matus et al., 2011), attenuating translation, promoting
degradation of misfolded proteins via ER-associated degradation (ERAD; Travers et al.,
2000), and promoting autophagy (D. a T. Nijholt et al., 2011). Prolonged ER stress can
trigger apoptosis (Ron & Walter, 2007; Rutkowski et al., 2006).
The PERK arm of the UPR acts primarily on translation. When PERK is activated
(thus becoming phosphorylated PERK, or pPERK), a kinase domain on the cytosolic
side of the protein phosphorylates eukaryotic translation initiation factor 2α (eIF2α or
peIF2α when phosphorylated). peIF2α is a less active form of the protein, and its
decreased efficiency slows general translation initiation and promotes translation of
activating transcription factor 4 (ATF4). ATF4 promotes transcription of genes that
enhance amino acid uptake and protect against oxidative stress (Harding et al., 2003).
Elements of the PERK pathway are also involved in regulating autophagy, a process that
degrades misfolded proteins (Bernales et al., 2006; Rouschop et al., 2010). Thus,
genetic variation that results either in alteration of PERK protein function or significant
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changes in the amount of PERK would perturb several crucial stress-response
pathways.
Several neurodegenerative disorders, including PSP, are characterized by
pathological aggregates of misfolded proteins in the brain. Previous work showed that
the UPR is activated in post-mortem AD brains (Jeroen J M Hoozemans et al., 2009), as
well as in the brains of patients with frontotemporal lobar degeneration with tau
inclusions (FTLD-tau) (D. A. T. Nijholt et al., 2012), PD (J J M Hoozemans et al., 2007),
amyotrophic lateral sclerosis (ALS; Atkin et al., 2008; Wang et al., 2010), and multiple
system atrophy (MSA; Makioka et al., 2010). Nijholt et al. (2011) reported evidence of
UPR activation in the hippocampus and, to a lesser extent, the locus ceruleus and
putamen of PSP patients.
We investigated activation of PERK and eIF2α in postmortem brains from subjects
with PSP and AD, as well as from normal elderly subjects. We used antibodies that
recognize the phosphorylated species of PERK and eIF2α, i.e. the activated forms of
these 2 proteins (pPERK and peIF2α, respectively). Our primary goal was to investigate
the brain regions most affected by tau pathology in PSP. We searched for evidence of
PERK and eIF2α activation in the pons, medulla and midbrain, regions affected in PSP,
in the hippocampus and frontal cortex, which are regions affected in AD, and in the
cerebellum, a brain region which is relatively spared in both diseases, although the deep
cerebellar nuclei and cerebellar cortex may harbor modest amounts of tangles and
plaques, in PSP and AD, respectively. We also looked at PERK and eIF2α activation in
young controls to determine if ER stress is activated in normal aging. Our results
indicated that PERK and eIF2α activation parallels the pattern of neuropathology in PSP
and AD. In normal hippocampus, activation increases with age and correlates with tau
but not Aβ amyloid pathology. We also examined coding haplotypes that were
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previously shown to affect PERK activation (Liu et al., 2012). We found that the
haplotype that corresponds to the highest PERK activation is in linkage disequilibrium
(LD) with the high risk allele of the top PSP GWAS marker, indicating that UPR
activation increases PSP risk and is not a protective response in PSP.
MATERIALS AND METHODS
Human Tissue
We obtained postmortem human pons, medulla, midbrain, frontal cortex, hippocampus,
and cerebellum samples from the Center for Neurodegenerative Disease Research
(CNDR; University of Pennsylvania School of Medicine, Philadelphia, PA) using the
CNDR Integrated Neurodegenerative Disease Database (Xie et al., 2011) and from the
Michigan Alzheimer's Disease Research Center Brain Bank (MADRC; University of
Michigan, Ann Arbor, MI). We chose PSP and AD cases for lack of co-morbid
diagnoses and availability of fixed tissue-- PSP and AD cases with a secondary
neuropathological diagnosis (NPDx; for instance, PD) were excluded from the present
study. All PSP and AD cases were evaluated by a neurologist pre-mortem and referred
to the CNDR or MADRC brain donation programs, where a neuropathologist made a
NPDx according to established criteria (Hyman & Trojanowski, 1997; Litvan et al., 1996).
Controls had no clinical history or postmortem diagnosis of a neurodegenerative
disease. One control displayed a moderate amount of Lewy body pathology in the
medulla and another displayed a mild amount of tau deposition in the midbrain (though
not in the substantia nigra). All control cases were free of Lewy bodies in the
hippocampus. We age-matched all cases and controls (See Table 2.1 and Table 2.S1
for demographic information). Tissue used for immunohistochemical and
immunofluorescence studies was fixed in either ethanol (70%) or 10% neutral buffered
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formalin overnight and then processed for paraffin embedding and 6µm thick sections
were generated as described (Heiko Braak et al., 2006) using a Leitz 1512 microtome.
The average age of PSP, AD, and normal controls was approximately 75 years. Average
disease duration for PSP patients was 6.7 years, while the average duration for AD
patients was 10.8 years. The average post-mortem interval (PMI) for all cases was 10.2
hours (Table 2.1, Table 2.S1). Pontine sections included the locus coeruleus and
surrounding tegmentum, midbrain sections included the substantia nigra, medulla
sections included the olivary nucleus, hippocampal sections included the CA and
dentate regions, frontal cortex sections included both white and gray matter, and
cerebellar sections included the folia.
Immunohistochemistry
Immunohistochemistry was performed as previously described (Arnold et al., 2010;
Lippa et al., 2009). We deparaffinized brain sections on slides using xylene (Mallinckrodt
Baker Inc., Phillipsburg, NJ), and then hydrated them through a series of ethanol
washes, and quenched endogenous peroxidases by immersing sections in a mixture of
hydrogen peroxide and methanol. Following a wash in running water, we performed
antigen retrieval by microwaving sections immersed in citrate buffer (Thermo Shandon
Limited, Astmoor, WA). We then washed sections in 0.1M Tris (pH 7.6; Fisher
Scientific), blocked in 0.1M Tris (pH 7.6)/2% fetal bovine serum (FBS), and applied
primary antibody (incubated overnight at 4o). This wash/block procedure was identical
for secondary antibody application, with an incubation time of one hr. Following another
wash, we applied avidin/biotin complex (Vector Labs) to each section and incubated the
sections for one hr. Finally, we developed sections with DAB chromagen (Biogenex),
counterstained with hematoxylin, dehydrated through a series of ethanol and xylene
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washes. Cover slips were sealed with Cytoseal (Richard Allen Scientific, Kalamazoo,
MI). Antibodies used are listed in Table 2.2.
Immunofluorescence (IF)
We deparaffinized, hydrated, quenched, and performed antigen retrieval on slidemounted sections as described above. We then blocked sections in 0.1M Tris/2% FBS,
and applied mouse and rabbit primary antibodies (diluted in 0.1M Tris/2% FBS). Primary
antibody incubation time was 2 hr at room temperature. Following a wash in 0.1M Tris
and transfer to a “dark” chamber, we applied secondary antibodies (goat-anti-mouse and
goat-anti-rabbit; Vector Labs) and let sections incubate for another two hours at room
temperature. We then washed the sections again and applied 0.3% Sudan Black in 70%
ethanol (Romijn et al., 1999) for five min to quench endogenous lipofuscin related
flourophores. After another wash, the sections were coverslipped using Vectashield
(with DAPI; Vector Labs; Uryu et al., 2003).
Slide Scoring and Analysis
pPERK and peIF2 antibodies both stained cells in a characteristic punctate pattern (Fig.
2.1a and 2.2a; (J J M Hoozemans et al., 2007; Jeroen J M Hoozemans et al., 2009). We
scored each tissue section for pPERK or peIF2α IHC staining according to the following
scale: negative (-): no cells stained, rare (R): 1-3 cells stained, +: 4-20 cells stained, ++:
20+ cells stained, could have diffuse distribution of stained cells, may have high density
of stained cells in some fields of the section, +++: high density of stained cells in almost
every field of the section. A second rater confirmed scores in 20% of randomly selected
slides (see Fig. 2.S1). For double IF of hyperphosphorylated tau (htau) and pPERK, we
visualized and photographed 10 fields per section and manually counted the number of
htau positive cells, the number of pPERK positive cells, and the number of cells positive
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for both pPERK and htau. We scored all sections blind to disease group on an Olympus
CHBS microscope (IHC) or an Olympus BX60 Transmitted-Reflected Light Microscope
with BF/DF/DIC/Polarized Light and a SPOT RT Color digital microscope camera (IF).
Statistical analysis
We used Spearman correlations to examine correlations between level of tau pathology
vs. pPERK staining and age vs. pPERK staining, Fisher’s exact test to examine
association between disease condition and pPERK/peIF2α staining, Chi Square to
examine sex distribution among disease/normal groups, ANOVA to examine the mean
difference among disease/normal groups for average age at death and post-mortem
interval, and a Student’s t-test to examine the mean difference between disease groups
for average age of onset. All statistical analyses were two-sided. Statistical significance
was set at the 0.05 level unless otherwise indicated.
Analysis of linkage disequilibrium around rs7571971.
In a recent GWAS for PSP risk loci (Höglinger et al., 2011), a significant association was
established between PSP risk and rs7571971. This SNP falls in an intron of EIF2AK3,
the gene encoding PERK. While it is reasonable to assume the SNP somehow affects
risk for PSP by affecting expression of EIF2AK3, it remains to be proven. To garner
genetic evidence for this hypothesis, we first evaluated the pattern LD in sequence data
from the 1000 Genomes project (Abecasis et al., 2012) and pairwise LD evaluated using
SNAP (Suite of Nucleotide Analysis Programs, Johnson et al., 2008). Based on these
results, we genotyped 1043 PSP patients using TaqMan SNP Genotyping Assays
(Applied Biosystems, Foster City, CA) for the following four SNPs: rs7571971, rs867529
(S136C), rs1805165 (S704A), and rs13045 (R166Q; Table 2.3). All cases were
autopsied and had a neuropathologic diagnosis of PSP (Hauw et al., 1994). Genotyping
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was done according to manufacturer’s protocol. PCR conditions were as follows: 95°C
for 10 minutes, then 50 cycles of 92°C for 15 seconds, 60°C for 1 minute, 4°C for 2
minutes. Genotypes were visualized and called using a 7900HT Fast Real Time PCR
System and the allelic discrimination function of Sequence Detection System V.2.4
(Applied Biosystems, Foster City, CA). Finally, we phased the resulting four-SNP
genotypes using eHap software (Seltman, Roeder, & Devlin, 2003), which provides
maximum likelihood estimates of haplotype frequencies.
RESULTS
The PERK arm of the UPR is activated in PSP
To determine whether the UPR is activated in PSP, we stained post-mortem human
brain tissue from PSP and AD patients as well as normal elderly controls using
antibodies against pPERK and peIF2α, the activated forms of these proteins. We chose
six brain areas to stain for PERK and eIF2α activation: the pons, medulla, and midbrain
(affected in PSP), the hippocampus and frontal cortex (affected in AD), and the
cerebellum, which is relatively spared in both diseases.
In PSP cases, of the regions tested, the pons, medulla, and midbrain
demonstrated the highest degree of pPERK and peIF2α staining (Fig. 2.1b, Fig. 2.2b,
Fig. 2.3a-c, and Fig. 2.4a-c) as measured by number of cells showing staining per field
(Fig. 2.S1). These are the brain areas most affected by tau pathology in PSP. pPERK
and peIF2α staining was punctate and cytoplasmic with some non-specific nuclear
staining (Fig. 2.1a and Fig. 2.2a), a pattern observed by others in AD and PD (J J M
Hoozemans et al., 2007; Jeroen J M Hoozemans et al., 2009). In the pons, all PSP
cases showed some cells positive for both pPERK and peIF2α. pPERK was observed in
the medulla and midbrain in all but one case for each region. For peIF2α, all cases
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showed positive cells in the medulla and all but one case showed positive cells in the
midbrain.
PSP cases as a group showed significantly more pPERK and peIF2α staining in
the pons, medulla, and midbrain compared to elderly controls. For pPERK, only one
control subject (age 63) showed “rare” positive cells in the pons and medulla. This is not
the same control subject that displayed Lewy body pathology in the medulla. In the
midbrain, very few controls were positive for pPERK. For peIF2α, most controls were
negative in these brain areas except for a single subject with rare positive cells in the
medulla. For AD, there were more positive cases with a higher density of positive cells
compared to controls but less than found in PSP (Fig. 2.3 and 2.4, a-c, Table 2.3).
In the hippocampus and frontal cortex, AD cases as a group scored significantly
higher than PSP or normal elderly controls for both pPERK and peIF2α staining (Table
2.3). pPERK and peIF2α staining was especially strong in the AD hippocampus, with
nearly all cases demonstrating high levels of positive cells. All PSP cases had mild to
moderate pPERK staining in the hippocampus, though not all cases demonstrated
peIF2α staining. Surprisingly, many normal elderly controls demonstrated at least a mild
level of pPERK and peIF2α positive cells in the hippocampus (Fig. 2.1c, Fig.2.2c, Fig.
2.3d, and Fig. 2.4d). Staining was generally milder in the frontal cortex than in the
hippocampus, although AD cases still scored significantly higher than PSP cases or
normal controls (Fig. 2.3e and Fig. 2.4e). PSP cases scored significantly higher than
normal controls for pPERK staining but not for peIF2α staining (Table 2.3). Notably, the
pons, medulla, and midbrain are severely affected in PSP [2] but only moderately or
mildly affected in AD (Serrano-Pozo, Frosch, Masliah, & Hyman, 2011). Conversely, the
hippocampus and frontal cortex are strongly affected in AD (Serrano-Pozo et al., 2011),
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but only mildly affected or unaffected in PSP. Thus, PERK activation is strongest in
areas of the brain highly affected by pathology in PSP and AD. Nearly all cases were
negative for pPERK and peIF2α in the folia of the cerebellum (Fig. 2.1d, Fig. 2.2d, Fig.
2.3f, and Fig. 2.4f), although one AD case showed rare staining in this area. Regardless,
there is generally little to no pathology in this area in PSP or AD, and thus our findings
are consistent with the inference that pathology and PERK activation occur in the same
disease-affected brain areas.
Activation of pPERK in hTau Positive Cells
We were interested in whether the UPR is activated in cells affected by tau pathology.
We performed double immunofluorescence staining for pPERK and htau on sections of
pons and hippocampus in PSP, AD, and normal controls (Fig. 2.5a). In PSP pons, an
average of 72% of pPERK positive cells were also positive for htau. However, only 43%
of htau positive cells were also positive for pPERK (Fig. 2.3c). This substantial overlap is
in contrast to AD hippocampus, in which only 20% of pPERK positive cells also stained
for htau and only 12% of htau positive cells stained for pPERK (Fig. 2.3d). Overlap
between htau and pPERK staining was also low in PSP and normal hippocampus (data
not shown). In the pons, overlap between pPERK puncta and htau occurred mostly in
cells with diffuse, cytoplasmic htau staining rather than dense, fibrillar staining (Fig.
2.3b). This suggests that PERK is activated in pre-tangle neurons. Hoozemans et al.
(2009) described similar distribution of htau/pPERK staining in AD hippocampus.
PERK is activated in normal hippocampus
Unexpectedly, we found pPERK and peIF2α staining in the hippocampus of agematched elderly normal controls as described above. To follow up on this finding, we
expanded our initial control hippocampus sample to include cases with a wide range of
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ages (range: 16-92, mean: 52.4; see Table 2.S1). We found that age significantly
correlated with the pPERK staining score (Fig. 2.6a). The older the subject, the more
likely they were to have high levels of PERK activation in the hippocampus. However,
not all aged normal controls demonstrated hippocampal pPERK activation although
some subjects at all ages examined here were negative for pPERK staining.
We also found that the level of tau pathology correlated with pPERK staining.
The more tau pathology (as measured by PHF-1 staining) in a normal hippocampus, the
more likely that the hippocampus was also positive for activated PERK (Fig. 2.6b). All
controls negative for pPERK staining were also negative for htau staining; cases with
severe pPERK staining scores also scored high for htau. This correlation was significant
(Spearman R: 0.7523, p = .0002). There was no correlation between pPERK staining in
the hippocampus and Aβ amyloid plaque pathology (as measured by Thioflavin S
staining to detect senile plaques); all normals with high pPERK scores and relatively
high tau scores in the hippocampus were negative for Aβ amyloid plaques and Lewy
bodies (data not shown).
PERK protein coding variants are associated with PSP risk
Alleles at rs7571971 are significantly associated with PSP risk [10]. To identify other
SNPs in high linkage disequilibrium with rs7571971, we evaluated 1000 Genomes data
for subjects of European ancestry. As assessed by LD measure r2 (Devlin & Risch,
1995), 14 SNPs were in high LD with rs7571971 (r2 > 0.8), including the 3 nonsynonymous coding variants. Of these 14, none fell in the coding region of any gene
besides EIF2AK3 and all but 5 fell within EIF2AK3 (Table 2.5).
The 3 non-synonymous coding variants in EIF2AK3 were Ser136Cys,
Arg166Gln, and Ser704Ala. When haplotypes were constructed from 1000 Genome
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data, there were two common haplotypes Ser-Arg-Ser (haplotype A) and Cys-Gln-Ala
(haplotype B) with predicted frequencies of 0.64 and 0.29, respectively; one uncommon
haplotype, Ser-Gln-Ser (haplotype D), with a frequency of 0.06; and 4 rare haplotypes of
frequency close to 1/1000 . The top PSP GWAS SNP for this gene is rs7571971, a 2allele polymorphism in EIF2AK3 intron 2 with a minor allele frequency of 0.25-0.28
(Höglinger et al., 2011). From the 1000 genome analysis, the minor allele for rs7571971
is almost perfectly correlated with haplotype B and the major allele with haplotypes A
and D.
To confirm the relationship of LD amongst SNP alleles in PSP subjects, we
genotyped 1,043 PSP cases for rs7571971, and the 3 coding variant SNPs. The
genotypes for these four SNPs were then phased using maximum likelihood. We
observed that, in PSP cases, haplotype frequencies were almost identical to those from
1000 Genomes data: for A, 0.645 versus 0.642; for B, 0.288 versus 0.301; and for D,
0.061 versus 0.053. Again haplotypes A and D are completely correlated with rs7571971
allele C (Fig. 2.7), the protective PSP allele. Haplotype B is completely correlated with
allele T, the high risk PSP allele. Recently Liu et al (2012) showed that when
lymphoblastoid cell lines are treated with thapsigarin to induce ER stress, cells
homozygous for the B haplotype showed stronger activation than cells homozygous for
the A haplotype. Thus B is the high-risk haplotype for PSP suggesting that activation is
not a protective response, but rather increases risk for PSP.
DISCUSSION
We found that PERK is activated in disease-affected brain regions in PSP,
including the pons, medulla, and midbrain. We also found that PERK’s downstream
effector, eIF2α, is activated similarly in PSP brainstem areas. In contrast, PERK and
eIF2 are not activated or only weakly activated in normal and AD brainstem,
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respectively. We confirmed that AD cases have strong immunoreactivity for pPERK and
peIF2α in the pyramidal cells of the hippocampus (Jeroen J M Hoozemans et al., 2009)
and in the frontal cortex. In contrast, PSP cases show mild to moderate pPERK
staining in these regions (D. A. T. Nijholt et al., 2012). PERK and eIF2α were not
activated in the cerebellum in either disease. In AD and PSP, the pattern of UPR
activation parallels the regional distribution of pathology in these two disorders.
We explored the relationship between abnormal tau deposits and UPR activation
in the PSP brainstem. Although there is some overlap between cells with activated
PERK and cells with htau, at least half of htau-positive cells do not have concurrent
PERK activation. A greater proportion of pPERK positive cells were also positive for tau,
but 25% stained for pPERK alone. Thus, although PERK is activated in brain regions
highly affected by tau pathology, htau and pPERK do not necessarily overlap at the
single cell level. One potential explanation for lack of complete overlap may be that
PERK activation precedes tangle formation, and is no longer activated in cells with
mature tangles. We found that overlap between pPERK and htau mostly occurred in
cells with diffuse htau staining rather than dense tau staining, supporting this hypothesis.
Similarly, Hoozemans et al. (2009) found that cells in the AD hippocampus that were
positive for pPERK also stained for markers of early tau aggregation (Jeroen J M
Hoozemans et al., 2009). This evidence suggests that PERK activation may temporally
precede overt tau aggregation, and could be triggered by immunohistochemically
undetectable levels of abnormal tau. The genetic data implicating both PERK and tau in
PSP supports a plausible temporal relationship between PERK activation and tau
aggregation.
Genetic findings (Höglinger et al., 2011) and the data presented here implicate
PERK as well as the UPR in the pathogenesis of PSP.

Genetic findings also associate

MAPT with PSP (Höglinger et al., 2011; Poorkaj et al., 2002; Rademakers et al., 2005;
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Tsuboi, Josephs, Cookson, & Dickson, 2003), and along with the presence of
aggregated tau as the key neuropathologic feature of PSP, these data clearly establish
that tau is intimately linked to PSP pathogenesis. While the UPR is activated by
misfolded proteins within the ER, and aggregated misfolded tau occurs in PSP, AD, and
other tauopathies, tau is a cytosolic protein and does not appear to traffic through the ER
as part of a secretory pathway. In normal neurons, most tau protein is intracellular and
attached to microtubules. In tauopathies, tau aggregates in the cytoplasm of cells, in
cellular processes, and at nerve terminals, but there is no evidence that tau aggregates
in the ER. Recent work in mouse models of α-synucleinopathies and studies on PD
autopsy material (E. Colla et al., 2012; Emanuela Colla et al., 2012) suggest that small
amounts of α-synuclein can be found in ER, and that in the disease state, these levels
are elevated, thereby activating the ER stress response. Still, since there is no direct
evidence that tau traffics through the ER, or evidence of tau aggregates in the ER, it is
unlikely that misfolded tau directly activates the canonical UPR. This view is supported
by the fact that in PSP, pPERK and pEIF2α are activated in cells with no observable tau
pathology, but we cannot exclude the possibility that very low or undetectable levels of
aggregated tau are present. Rather, a more likely explanation is that tau-induced
cytoplasmic events act to trigger the UPR by an unknown mechanism, which in turn
influences the degradation of tau. A possible mechanism is that cytoplasmic aggregated
tau may inhibit processes such as the ERAD-proteosome pathway used by cells to
degrade misfolded ER proteins, and thus preventing the normal degradation of these
proteins, stimulating ER stress (Abisambra et al., 2013).
PERK and eIF2α are also activated in pathology-associated regions of a number of
other neurodegenerative diseases, including another tauopathy, AD (Jeroen J M
Hoozemans et al., 2009). The UPR is also activated in non-tau diseases that include
ALS where UPR activation is observed in the spinal cord in sporadic cases (Atkin et al.,
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2008), and in PD where UPR activation occurs in the substantia nigra (J J M
Hoozemans et al., 2007). Expanded-repeat huntingtin, the pathological protein in
Huntington’s disease, induces ER stress in culture (Lajoie & Snapp, 2011). Notably,
these diseases share a common pathology, i.e. the accumulation of abnormal
aggregated proteins in the CNS. Thus, there may be a common mechanism by which
aggregated cytoplasmic proteins activate the UPR. The genetic association between
PERK and PSP suggests that this UPR activation can influence the disease process, at
least in the case of PSP.
Surprisingly, we found that 10/14 normal controls over 50 years of age had at
least minimal activation of pPERK in the hippocampus. This is in contrast to previous
studies that report no pPERK staining in this region in normal controls (D. A. T. Nijholt et
al., 2012). In these subjects, the degree of pPERK immunoreactivity correlated positively
with both the degree of htau immunoreactivity and age, but did not correlate with amyloid
pathology. The presence of at least some tau pathology in the hippocampus of normal
subjects is consistent with work by others (Heiko Braak, Thal, Ghebremedhin, & Del
Tredici, 2011), and could potentially indicate either pre-clinical AD or early neurofibrillary
tangle predominant dementia (NFTD). However, in the absence of clinical symptoms, it
is not possible to make either diagnosis. These findings in normal controls are consistent
with the idea that the activation of the UPR is due to the tau pathology and not the
amyloid pathology.
We reported strong genetic evidence that EIF2AK3 genotypes confer risk for
PSP (Höglinger et al., 2011). The strongest signal comes from single nucleotide
polymorphism (SNP) rs7571971 that is within EIF2AK3. There are several nonsynonymous coding polymorphisms in EIF2AK3 that track with risk and EIF2AK3
appears to be the gene in this region involved in PSP. However, another less likely but
still plausible explanation is that PSP risk in this region comes from a regulatory element
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that is intronic, within EIF2AK3, or in a close by intergenic region and that this element
controls expression of another gene. Also, the true PSP association could be from
nearby genes (e.g. FOXI3 or RPIA) though this is less likely since the signal from SNPs
in highlighting these genes are not as significant as SNPs within EIF2AK3. The work
presented here clearly demonstrates that in PSP, PERK is activated in a region-specific
pattern that matches regions where neurodegeneration occurs. Thus this functional
evidence along with the strength of the genetic evidence indicates that EIF2AK3 and not
an adjacent locus is the gene that confers risk for PSP.
The SNP giving the strongest EIF2AK3 signal in the PSP GWAS (rs7571971) is
intragenic in intron 2. This SNP is in strong disequilibrium with 3 EIF2AK3 exonic SNPs
which are non-synonymous. This relationship was predicted using 1,000 Genomes data
and confirmed here in PSP subjects (Fig. 2.7). These coding variants form two common
(A and B) and one rare haplotype (D). In PSP subjects, the low risk allele [C] at
rs7571971 completely correlates with haplotypes A and D while the high risk rs7571971
allele [T] completely correlates with haplotype B (Fig. 2.7).
Work in lymphoblastoid cell lines (Liu et al., 2012) with different haplotypes show
that expression of EIF2AK3 is not altered by these haplotypes. However, when the
PERK arm of the UPR is activated by thapsigargin, PERK from haplotype B homozygote
cells is more active in phosphorylating eIF2α when compared to PERK from cells
homozygous for haplotype A. The haplotype that confers high risk for PSP produces the
more active form of PERK, suggesting that activation of the UPR is pathogenic in PSP
and not a protective response. This is consistent with observations in prion protein
induced neurodegeneration. Moreno et al., showed that during prion replication,
synaptic failure and neuronal loss is temporally associated with UPR activation and
inhibition of translation. When translation is restored using over-expression of GADD34
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to dephosphorylate eIF2α, survival of infected animals is prolonged. In contrast, when
the UPR is activated using salubrinal, survival is decreased (Moreno et al., 2012). Both
observations are consistent with activation of the PERK/eIF2α arm of the UPR
enhancing neurodegeneration, as proposed here for PSP.
The two low risk haplotypes (haplotype A, Ser-Arg-Ser; and haplotype B, SerGln-Ser) differ only at the middle amino acid, 166— this amino acid is unlikely to
functionally influence PERK activation. The low and high risk (Haplotype B, Cys-GlnCys) haplotypes differ at both positions 166 and 704, and one or both may influence
PERK activity. Amino acid 166 is on the portion of PERK that is in the ER lumen and
positioned where this protein senses mis-folded proteins. Position 704 is on the
cytoplasmc side of PERK, a segment of the protein that is phosphorylated when
activated and that has the active site for phosphorylating eIF2α. Additional work is
needed to confirm that haplotype B PERK is the more active protein and to determine if
mis-folded protein sensing or activation via auto phosphorylation is affected.
Conclusions
The PERK protein and its downstream effector eIF2α are phosphorylated in diseaseaffected regions in both PSP and Alzheimer’s disease. A previous study using PSP
samples described UPR activation primarily in the hippocampus, a brain region not
affected in this disease (D. A. T. Nijholt et al., 2012). In contrast, we examined a large
panel of brain areas (pons, medulla, midbrain, hippocampus, frontal cortex, and folia of
the cerebellum) from PSP and AD cases as well as normal controls to show that this
activation is disease-specific in its geographic distribution in the brain. In contrast to
previous reports, we also found UPR activation in the hippocampus of a subset of our
normal controls, a completely novel finding. This activation positively and significantly
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correlated with both age and amount of tau pathology. This suggests that tau and UPR
activation are linked. We also demonstrated a genetic association between an EIF2AK3
protein coding haplotype and PSP, indicating that variation in the PERK protein affects
PSP risk.
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Table 2.1 Subject information.

n

Avg
Age of
Onset

15

N/A

12

Normal - total
PSP

Normal – agematched
Normal – non
age-matched

AD

Avg Age
at Death

Avg Disease
Duration

% Female

Avg PMI

71.7(8.4)

N/A

46.7

12.7(8.5)

N/A

54.5(24.9)

N/A

66.7

9.1(3.4)

27

N/A

64.0(19.4)

N/A

56.7

11.1(6.9)

17

66.8(5.8)

73.7(5.2)

6. 7(2.2)

64.7

11.7(6.0)

9

65.0(6.3)

75.8(5.1)

10. 8(3.4)

44.4

9.4(5.8)

There were no significant differences between groups for average age at death
(ANOVA, p = 0.33), post-mortem interval (ANOVA, p = 0.54), average age of onset (PSP
and AD only, Student’s t-test, p = .45) or percent female (Chi Square, p = 0.89). Average
disease duration for AD was significantly longer than for PSP (Student’s t-test, p =
0.002). Standard deviations indicated inside parenthesis
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Table 2.2 Anitbodies used.
Antigen
pPERK
Primary
peIF2α
AT8
goat α rabbit IgG
Secondary goat α rabbit IgG
goat α mouse IgG

Epitope
pThr981
pSer51
pSer202/pThr205
biotin
AlexaFluor 488
AlexaFluor 594
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Source
Santa Cruz
Sigma-Aldrich
Thermo Scientific
Vector Labs
Alexa
Alexa

Dilution
1:4000
1:2000
1:7500
1:1000
1:500
1:500

Table 2.3 P-values for comparison of pPERK and pEIF2α immunoreactivity in
PSP, AD, and normal controls for different brain regions.
Comparison
groups
AD vs. Normal
PSP vs. AD
PSP vs. Normal
Comparison
groups
AD vs. Normal
PSP vs. AD
PSP vs. Normal

Pons
pPERK
peIF2α
3.4E-5
0.0045
3.8E-4 0.00049
3.8E-9

4.1E-5

Hippocampus

Medulla
pPERK
peIF2α
0.034
0.041
1.7E-4
0.028
6.1E-7

6.0E-6

Frontal Cortex

Midbrain
pPERK
peIF2α
0.0026
0.0037
4.0E-7
0.009
6.0E-6

1.4E-4

Cerebellum

pPERK
0.0006

peIF2α
0.0042

pPERK
4.1E-5

peIF2α
4.1E-5

pPERK
0.4

peIF2α

0.000021

8.2E-5

1.6E-4

0.0049

0.5

1

0.0034

0.073

0.0045

0.1

1

1

1

P-values are from a Fisher exact test. “E” indicates “x 10^”. pPERK and peIF2α staining
in PSP brainstem areas (pons, medulla, midbrain) were significantly greater than in AD
or normal brainstem areas. AD brainstem areas had significantly more pPERK and
peIF2α staining than normal brainstem areas. In contrast, primary AD-affected brain
areas (hippocampus, frontal cortex) had significantly more pPERK and peIF2α staining
than PSP or normal hippocampus and frontal cortex. There was no difference in staining
between AD, PSP, or normal brains in the cerebellum
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Table 2.4 PERK haplotypes.

Alleles (%)
Haplotype A
Haplotype B

rs867529-rs13045-rs1805165
GCA
CTC

Affected Amino Acids
Ser136-Arg166-Ser704
Cys136-Gln166-Ala704

Haplotype D

GTA

Ser136-Gln166-Ser704
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PSP (n=994)
1233 (62.5)
626 (31.7)
113

(5.7)

Table 2.5 SNPs in high LD with rs7571971.

SNP

Gene

Distance in base
pairs from GWAS
hit SNP

RSquared

DPrime

Coordinate_HG18

rs1805165

EIF2AK3

20460

0.889

1

88656006

rs6739095

EIF2AK3

15287

0.886

0.96

88661179

rs11898161

EIF2AK3

13703

0.925

1

88662763

rs1913671

EIF2AK3

4532

0.886

0.96

88680998

rs11681299

EIF2AK3

6381

0.889

1

88682847

rs867529

EIF2AK3

17922

0.889

1

88694388

rs6731022

EIF2AK3

21684

0.886

0.96

88698150

rs11684404

EIF2AK3

29271

0.886

0.96

88705737

rs11680549

EIF2AK3

30997

0.813

0.957

88707463

rs6547787

34385

0.886

0.96

88710851

rs1606803

37965

0.889

1

88714431

rs62157778

38739

0.889

1

88715205

rs13003510

46139

0.925

1

88722605

rs13001657

51260

0.888

0.96

88727726
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Table 2.S1 Individual Case Information
Case Demographics
Case
#
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
* 27
* 28
* 29
†* 30
† 31
† 32
† 33
† 34
† 35
† 36
†* 37
† 38
† 39
† 40
† 41
† 42
† 43
† 44
45

NPDx
PSP
PSP
PSP
PSP
PSP
PSP
PSP
PSP
PSP
PSP
PSP
PSP
PSP
PSP
PSP
PSP
PSP
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
AD

Sex
M
F
F
M
F
F
F
F
M
F
F
M
M
F
F
M
F
M
F
F
M
M
M
F
F
M
M
M
F
M
F
F
F
F
F
F
F
F
F
M
M
M
F
M
F

Age at
Death
73
70
79
73
72
71
81
77
85
75
76
67
70
78
64
72
60
60
75
70
67
90
74
83
75
83
63
70
67
65
89
72
51
92
68
85
65
56
46
47
38
16
33
29
71

Disease
Duration
6
7
11
4
5
6
7
11
3
5
8
10
6
8
7
7
3
-

12

39

Post-Mortem Interval
20.5
4.5
17
10.5
20
6.5
17
12.5

EIF2AK3
haplotype
A/B
A/A
B/B
A/A
A/A
A/B

12
8
12
11
8
21
3.5
3
14
3.5
10.5
10.5
6
7.5
3
15
14.5
5
19
5.5
26
7
4
5
5
32
14
19
12
12
11
12
8
7
12
17

B/B
A/A
A/A
B/B
A/D
A/B
A/A
B/D
A/B
A/D
A/A
A/B
A/B
A/A

A/B

46
47
48
49
50
51
52
53

AD
AD
AD
AD
AD
AD
AD
AD

M
F
F
M
M
M
M
F

85
72
81
70
77
74
73
79

13
17
11
10
6
12
10
6

6.5
12
4
5
4
7.5
9
20

A/A
A/B
A/A
B/B
A/B
A/B
A/A

Neuropathological diagnosis, sex, age at death, disease duration, post-mortem interval,
Braak stage, and hippocampal Aβ amyloid plaque score for all cases and controls used
† = hippocampus only
* = pons, cerebellum and/or hippocampus only.
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Figure 2.1 pPERK is activated in PSP, AD, and normal brain. a. Example of a cell
with pPERK immunoreactive puncta in the pons of a PSP case. b-d. Representative
fields showing pPERK staining of pons, hippocampus, and cerebellum in normal, PSP,
and AD cases. Scale bars are 50µm unless otherwise indicated
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Figure 2.2 peIF2α is activated in PSP, AD, and normal brain. a. Example of a cell
with peIF2α puncta in the pons of a PSP case. b-d. Representative fields from peIF2α
staining of pons, hippocampus, and cerebellum in normal, PSP and AD cases. Scale
bars are 50µm unless otherwise indicated

42

Figure 2.3 Frequency of pPERK staining scores in PSP, AD, and normal brain.
Distribution of pPERK staining scores. +++ = widespread activation, ++ = moderate
activation, + = diffuse activation, R = rare activation, - = no activation. Y-axis indicates
number of cases with a particular pPERK staining score. All P-values obtained using
Fisher exact test. a-c. PSP cases had the strongest pPERK staining in the pons (PSP
vs. Normal: p = 3.8E-9) and the medulla (PSP vs. Normal: p = 6.1E-7), as well as
moderate staining in the midbrain (PSP vs. Normal: p = 6.0E-6) which was affected in all
PSP cases. d-e. AD cases had the strongest pPERK staining in the hippocampus (AD
vs. Normal: p = 0.0006) and moderate staining in the frontal cortex (AD vs. Normal: p =
4.1E-5) both of which were affected in AD. f. No cases had significant pPERK staining in
the cerebellum
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Figure 2.4 Frequency of peIF2α staining scores in PSP, AD, and normal brain.
Distribution of peIF2α staining scores. +++ = widespread activation, ++ = moderate
activation, + = diffuse activation, R = rare activation, - = no activation. Y-axis indicates
number of cases with a particular peIF2α staining score. All P-values obtained using
Fisher exact test. a-c. PSP cases had the strongest peIF2α staining in the pons (PSP vs.
Normal: p = 4.1E-5) and the medulla (PSP vs. Normal: p = 6.0E-6), as well as moderate
staining in the midbrain (PSP vs. Normal: p = 0.00041) which was affected in all PSP
cases. d-e. AD cases had the strongest peIF2α staining in the hippocampus (AD vs.
Normal: p = 0.0042) and moderate staining in the frontal cortex (AD vs. Normal: p =
4.1E-5) both of which were affected in AD. f. No cases had significant peIF2α staining in
the cerebellum
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Figure 2.5 Hyperphosphorylated tau and pPERK partially co-localize in PSP pons
and AD hippocampus. a. Example of a neuron co-stained for htau (red) and pPERK
(green). Tau staining is widespread and diffuse. pPERK staining is punctate and
localized to the soma and proximal neurites. b. pPERK staining occurred mostly in cells
with diffuse, non-fibrillar htau staining. Cells with dense, fibrillar htau staining did not
stain for activated PERK (*). c. In PSP pons, most pPERK positive cells also stained for
htau (72%), whereas fewer than half of htau stained cells (43%) also stained positive for
pPERK. d. htau and pPERK staining overlapped very little in AD hippocampus (14% and
20%). Scale bars are 50µm unless otherwise indicated
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Figure 2.6 Severity of PERK activation in normal hippocampus correlates with age
and tau pathology. a. Plot of pPERK staining score (X-axis) versus subject age at
death (Y-axis). Each diamond represents one normal subject. Some individuals both
young and old were negative for pPERK staining. Of those that stained positive for
pPERK (including those showing rare through +++ levels of immunoreactivity), older
individuals tended to have more severe pPERK staining scores. b. Frequency table
plotting htau score against pPERK staining score in normal hippocampus. Htau score
and pPERK score were positively correlated (Spearman R: .7523; p=0.0002). The higher
the htau score of an individual hippocampus, the higher the pPERK staining score
tended to be. Htau scores were obtained from the CNDR Integrated Neurodegenerative
Disease Database[42] using antibody PHF-1
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Figure 2.7 Comparison of PERK haplotype with GWAS risk allele. A GWAS for PSP
identified a risk locus on chromosome 2 (rs7571971). The common, low risk allele at this
locus is cytosine (C) and the PSP risk allele is thymine (T) [10]. Among individuals
homozygous for C at this locus, all harbor PERK haplotype A or D in some combination.
Individuals heterozygous (C/T) at this locus were heterozygous for haplotypes A, B,
and/or D. Individuals homozygous for T at the GWAS risk locus were always
homozygous for PERK haplotype B. This demonstrates that one of the two amino acid
changes conferred by the B PERK haplotype that are not shared by the D haplotype
may be responsible for the PSP risk evident on Chr. 2
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Figure 2.S1 Scoring system examples. Representative fields from brain areas that
scored “-“ (negative), “R” (rare), “+” (mild staining), “++” (moderate staining), and “+++”
(heavy staining), along with scoring criteria.
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CHAPTER 3: FUNCTIONAL CONSEQUENCES OF PERK GENETIC VARIATION

Lauren D. Stutzbach1,2,4, Cagla Akay3,4, Patrick Gannon3,4, Kelly Jordan-Sciutto3,4,
and Gerard D. Schellenberg, PhD1,4.
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ABSTRACT
EIF2AK3, the gene that codes for the PERK protein, is associated with PSP disease
risk. There are two common protein coding variants of PERK, HapA and HapB, which
differ by three amino acids. Recent work indicates HapB PERK has more kinase activity
in response to thapsigargin treatment than does HapA in human β-lymphocytes (Liu et
al., 2012). This project had two goals: 1) replicate and expand upon previous findings in
β-lymphocytes and 2) determine which of the three amino acid coding changes is
responsible for the difference in PERK activity between HapA and HapB. This work
confirms that β-lymphocytes expressing HapB PERK show more eIF2α phosphorylation
than those expressing HapA. Paradoxically, HapB PERK cells also show less
phosphorylated PERK. These findings were echoed in mouse embryonic fibroblasts
expressing PERK variant constructs. Further work exploring the functional differences
between PERK variants is warranted.

INTRODUCTION
The PERK protein is part of the cell’s unfolded protein response (UPR). The
PERK arm of the UPR acts primarily on translation. When PERK is activated (thus
becoming phospho-PERK, or pPERK), a kinase domain on the cytosolic side of the
protein phosphorylates eukaryotic translation initiation factor 2α (eIF2α). peIF2α then
acts at the ribosome to slow down general translation initiation and promote translation
of ATF4 (Ron & Walter, 2007). ATF4 promotes the transcription of genes that enhance
import of amino acids and protect against oxidative stress (Harding et al., 2003).
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Three single nucleotide polymorphisms (SNPs) that confer coding changes to the
PERK protein are linked with disease risk for progressive supranuclear palsy (PSP;
Stutzbach et al., 2013). The more common coding variant, “Haplotype A,” is lower risk,
while the less common variant “Haplotype B” is higher risk (for amino acid sequences,
see Table 3.2). Work in human β-lymphoblastoid cell lines shows that the Haplotype B
form of PERK is more active in response to treatment with the UPR-inducing drug
thapsigargin (Liu et al., 2012).
The goal of this thesis project is to determine what role PERK and the UPR play
in PSP pathogenesis. I have done this by determining the distribution of activated PERK
in the post-mortem PSP-affected brain, examining the association between pPERK and
tau, and analyzing the genetic association between common variations to the PERK
protein and PSP (Stutzbach et al., 2013). The present analysis aims to expand on those
findings by determining the biological effects of PERK protein coding variants on PERK
function.
MATERIALS AND METHODS
Generation of PERK constructs
Human PERK cDNA clones were obtained from Transomic Technologies
(Huntsville, AL; Fig 3.1A). To create PERK variants, we performed site-directed
mutagenesis using the QuikChange Multi kit (Agilent Technologies, Santa Clara, CA).
For primers, see Table 3.1. All PERK variants were sequence-confirmed using CMV
primers (pTCN promoter for PERK insert; Fig. 3.1A and 3.1B).
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Cell Culture
We obtained human β-lymphocyte cell lines from Coriell Cell Repository
(Camden, NJ). Cell lines expressing PERK haplotype A were NA06985, NA06991,
NA06993, NA07029, NA07055; cell lines expressing PERK haplotype B were NA07348,
NA07357, NA10835, NA11993, and NA12249. We cultured β-lymphocytes in RPMI1640 media (Corning Cellgro, Manassas, VA) supplemented with 15% fetal bovine
serum (FBS), 1% L-glutamine, and 1% Pen Strep antibiotic. Drug treated cells were
dosed with 0.1μM thapsigargin (reconstituted in DMSO) for 30 minutes.
Mouse embryonic fibroblasts (MEFs) negative for the PERK protein were the
generous gift of the Constantinos Koumenis laboratory (University of Pennsylvania,
Philadelphia, PA) and originated from PERK knockout mice generated by the Douglas R.
Cavener laboratory (Pennsylvania State University, State College, PA). PERK knockout
was carried out using Cre-Lox recombination as described in Zhang P. et al (2002).
MEFs were cultured in Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 10% FBS, 1% L-glutamine, and 1% Pen-strep. PERK constructs and
the pTCN empty vector were tranfected into MEFs using Lipofectamine LTX with PLUS
reagent (Invitrogen, Carlsbad, CA) and cells were harvested 24 hours later. Drug-treated
cells were dosed with 0.1μM thapsigargin (reconstituted in DMSO) for 75 minutes before
harvest.
At harvest, all cells were washed twice with 1x PBS then (with the exception of
cells harvested for nuclear protein isolation) lysed using cell lysis buffer formulated by
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the David Ron laboratory in Cambridge, UK
(http://ron.cimr.cam.ac.uk/protocols/IP.IMMUNOBLOT.html), consisting of 1% TritonX
100, 150mM NaCl, 20mM Hepes pH 7.5, 10% glycerol, 1mM EDTA, 1x Halt
phosphatase inhibitor (Life Technologies, Thermo-Fisher Scientific, Rockville, IL), and
cOmplete protease inhibitor cocktail (Roche, Basel, Switzerland). Cells targeted for
nuclear protein isolation were harvested using the Biovision cell fractionation kit
(Milpitas, CA) according to manufacturer protocol. Cells harvested for PERK expression
analysis were lysed in TRI reagent (Ambion, Thermo Scientific, Rockford, IL) and RNA
isolated according to manufacturer protocol. Protein concentration for all cell lysates was
calculated using the Pierce BCA assay (Thermo Scientific, Rockford, IL) according to
manufacturer protocol.
PERK expression analysis
PERK null MEFs were transfected with 2.5 ug PERK cDNA using Lipofectamine
LTX with PLUS reagent (Invitrogen, Carlsbad, CA) and cells were harvested 24 hours
later using Tri reagent (Ambion, Thermo Scientific, Rockford, IL). RNA was isolated
according to TRI reagent manufacturer protocol. RNA from PERK-transfected cells was
reverse-transcribed into cDNA using High Capacity Reverse Transcription Kit (Applied
Biosystems, Foster City, CA) and transcript levels quantified using qPCR TaqMan
Assays designed to detect PERK (Hs00178128_m1 and Hs00984006_m1; Applied
Biosystems, Foster City, CA) according to manufacturer protocol (50o C 2min, 95oC
10min, 40x: 95oC 15sec, 60oC 1min). PCR results were quantified and analyzed using
the ∆∆CT (cycle threshold) relative quantification method in Expression Suite software
(Applied Biosystems, Foster City, CA). Endogenous control was Hprt
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(Mm01545399_m1). Relative Quantification (RQ) values (fold change compared to
calibrator sample [HapA]) greater than 2 or less than 0.5 were considered significant
(https://genomique.iric.ca/resources/files/How_to_deal_with_qPCR_results.pdf).
Western blotting
Cell lysates were combined with Lane Marking Reducing Sample Buffer (Thermo
Scientific, Rockford, IL) and boiled for 10 minutes before loading onto 4-20% Tris-HCL
Criterion gels (BioRad, Hercules, CA). Proteins were transferred to PVDF membrane,
blocked in 5% non-fat milk for one hour or 5% bovine serum albumin (for peIF2α
detection only) for one hour, then incubated in primary antibody overnight. Blots were
washed in Tris-buffered saline with 1% Triton-X 100 (Roche Boehringer Mannheim,
Basel, Switzerland; TBS-T), incubated in secondary antibody for two hours, washed
again, then incubated in Luminata Forte or Crescendo Western substrate (Millipore,
Bilerica, MA) for five minutes. Each blot was exposed to film for a variable length of time
and developed in a Xomat 200A Professional developer (Kodak, Rochester, NY). For
antibody sources and concentrations, see Table 3.2.
Western blot analysis
Western bands were quantified using ImageJ image analysis software
(http://imagej.nih.gov/ij/). Each band was normalized first to its corresponding loading
control: total eiF2α was the loading control for peIF2α, and a 125 kDA protein band from
a Fast Green protein stain was the loading control for total PERK, pPERK, and ATF4. In
the MEF experiment, each pPERK, ATF4, and peIF2α band was then normalized to its
corresponding total PERK band to correct for variability in PERK expression. All values
reported represent normalized relative density values for each band.
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RESULTS
Thapsigargin treatment
To determine the optimal treatment duration for thapsigargin treatment, I
performed a time course analysis of eIF2α phosphorylation in PERK null (P -/-) MEFs
expressing human PERK. I transfected cells with HapA PERK and treated with 0.1μM
thapsigargin (tg) for 5, 15, 30, 45, 75, 90, 105, and 120 minutes before harvest. peIF2α
levels increased steadily with longer treatment times, peaking at 75 minutes and
remaining strong through 105 minutes (Fig. 3.2 A-B). For all subsequent experiments,
treatment time in P -/- MEFs expressing human PERK constructs was 75 minutes.
PERK expression analysis
To confirm uniform transfection and expression, I transfected P-/- MEFs with
each PERK construct and harvested RNA at 24 and 48 hours to perform qPCR. The
results of two Taqman Gene Expression Assays (Life Technologies) for PERK
demonstrated no significant differences in PERK transcript level between constructs (for
construct information, see Fig. 3.1 and Table 3.2); RQ values were less than 2 and
greater than 0.5 (Fig. 3.3; see Methods section). However, PERK transcript levels in
general were higher at 24 hours post-transfection (ptf) than at 48 hours ptf. Therefore,
cells were harvested at 24 hours ptf for all subsequent PERK transfection experiments.
PERK haplotype comparison in human β-lymphocytes
Liu et al. (2012) showed that human β-lymphocytes (β-L) homozygous for PERK
HapB have higher levels of eIF2α phosphorylation in response to tg treatment than β-Ls
homozygous for haplotype A. In order to replicate and expand upon this finding, I
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harvested cell lysates from four β-L lines homozygous for HapA and four homozygous
for HapB, with and without 0.1μM tg treatment (30 min). All cell lines were sequenceconfirmed homozygotes for HapA or HapB (see Methods for cell line information). I then
probed for total PERK, pPERK, total eIF2α, peIF2α, and β-actin (loading control) by
Western blot (Fig. 3.4A).
Total PERK levels did not vary between HapA and HapB, with or without tg
treatment (Fig. 3.4B). However, phosphorylated PERK (pPERK) levels were significantly
lower in HapB lines in comparison to HapA lines in both untreated and tg treated cells
(Fig. 3.4C; for total PERK and pPERK antibody information, see Table 3.3). This is in
contrast to significantly higher peIF2α levels in HapB lines in comparison to HapA lines
(Fig. 3.4D). While these peIF2α findings replicate the results from Liu et al (2012), this
decrease in pPERK in HapB is a novel finding. This indicates that the increase in peIF2α
levels may be independent of PERK’s autophosphorylation status.
There are a number of potential explanations for this seemingly contradictory
finding. First, the changes to the PERK protein that make up HapB PERK may interfere
with the pPERK antibody epitope (Thr982), indicating a difference in detection of pPERK
rather than a difference in actual pPERK levels. However, it is also possible that the
amino acid differences between HapA and HapB on the N-terminal end of the protein
(S136C and R166Q) act to promote and stabilize PERK dimerization (thereby increasing
the likelihood of eIF2α kinase activity), while the change to the C-terminal, cytoplasmic
end of PERK (S704A, the change nearest to a protein kinase domain) decreases the
likelihood of PERK transautophosphorylation. Further investigation into how the protein
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coding differences between HapA and HapB affect post-translational modifications
would be needed to determine which of these explanations is more likely.
Another caveat to this finding is that the lower pPERK levels for HapB +tg seem
to be driven by only half of the Hap B cell lines (compare the last four lanes for pPERK in
Fig. 3.4A). Thus, there may be additional factors at work in these cell lines and further
study of additional HapB homozygotes would be necessary to confirm and expand upon
this finding.
PERK variant comparison in P-/- MEFs:
To determine which of the three protein coding variants that make up HapB is
responsible for the difference in eIF2α phosphorylation between HapA and HapB, I
created several PERK constructs with the goal of expressing each in PERK knockout
cells and measuring activity. These PERK constructs are listed in Table 3.2.
I expressed each of these constructs in P-/- MEFs obtained from the Koumenis
laboratory ( Zhang et al., 2002)and harvested cell lysates 24 hours post-transfection
(ptf). I then probed for total PERK, pPERK, total eIF2α, peIF2α, ATF4 (ATF4 probed in
nuclear lysates only), and β-actin by Western blot (Fig. 3.5, Fig. 3.10). I then performed
relative quantification analysis using ImageJ software (http://imagej.nih.gov) and
normalized each Western band first to a loading control (a band at approximately 125
kDa from a fast green protein stain) and then to PERK expression for that run.
Quantifications in Figures 3.6-3.9 represent the mean values from 4 independent
replicates of this experiment. To determine statistical significance, I performed unpaired
t-tests between each “test” construct (HapB, 136C, 166Q, 704A) and HapA for all
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measures. I also performed paired t-tests within each construct to compare expression
levels with and without thapsigargin treatment.
PERK levels were not statistically different between constructs in the absence of
tg treatment (Fig. 3.6A). However, tg treatment resulted in a dip in total PERK levels in
HapB (p=0.02) and 136C (p=.05) in comparison to HapA (Fig 3.6B). Because total
PERK levels for both HapB and 136C also tended to be lower in the absence of tg
treatment, these differences were likely just slightly magnified in the drug treatment
condition. Total PERK levels did not significantly change within each construct after tg
treatment (Fig 3.6C).
pPERK levels for HapB, 136C, 166Q, and 704A were not statistically different
from Hap A in the absence of tg treatment (Fig. 3.7A). However, pPERK levels were
slightly, albeit significantly, lower in 704A relative to HapA (p=.01; Fig. 3.7B). pPERK for
all constructs increased significantly with tg treatment (all p-values < 0.05; Fig. 3.7C). To
determine whether the magnitude of response to tg treatment differed between each
construct and HapA, I calculated the ratio of tg treated to untreated for pPERK levels.
The ratio of tg treated to untreated for each construct was not significantly different from
the tg treated to untreated for HapA, though tg treatment tended to have a greater
magnitude of effect on HapB (Fig 3.7D).
peIF2α levels for HapB, 136C, 166Q, and 704A were not statistically different
from HapA with or without tg treatment, and tended to be variable (Fig. 3.8A). HapB
peIF2α levels did tend to be slightly higher than those of HapA, but this difference was
nonsignificant (p=0.253; Fig 3.8B). peIF2α for all constructs did not increase significantly
with tg treatment (all p-values > 0.05), again likely due to variability (Fig 3.8C). Likewise,
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the ratio of tg treated to untreated for each construct was not significantly different from
the tg treated to untreated for HapA (Fig. 3.8D).
ATF4 levels for HapB, 136C, 166Q, and 704A were not statistically different from
HapA with or without tg treatment. However, as with peIF2α, HapB levels of ATF4
tended to be highest and HapA levels lowest (tg treatment condition), with the individual
amino acid variants showing an intermediate level (Fig. 3.9A-B). ATF4 for all constructs
did not increase significantly with tg treatment (all p-values > 0.05; Fig 3.9C), though this
may, again, be due to variability. The ratio of tg treated to untreated for each construct
was not significantly different from the tg treated to untreated for HapA (Fig. 3.9D).
DISCUSSION
In this study, I was able to replicate the finding from Liu et al (2012) that human
β-lymphocytes homozygous for PERK haplotype B demonstrate higher levels of eIF2α
phosphorylation in response to tg treatment than do β-Ls homozygous for PERK
haplotype A. I also found that HapB B-Ls showed lower pPERK levels in response to the
same treatment. Bearing in mind the newness of the pPERK antibody and the potential
for this antibody to have a weaker affinity for HapB PERK than HapA PERK, this finding
seems ripe for a follow-up study with a larger sample size comparing the two haplotypes.
If this effect can be replicated and expanded, the next step could be to examine how the
HapB version of the protein differs from HapA in either structure (perhaps a difference in
disulfide bonding conferred by the 136 S->C variation) or in post-translational
modifications (notably, potential phosphorylation sites S136 and S704, which are ablated
by HapB).
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Though PERK null MEFs transiently expressing different variants of the PERK
protein (HapA, HapB, 136C, 166Q, 704A) largely did not statistically differ from one
another in pPERK, peIF2α, or ATF4 levels, these results suggest a trend toward HapBexpressing cells having a stronger response to tg treatment. HapB expressing cells
showed a bigger difference between baseline levels of pPERK, peIF2α, and ATF4 and
these same levels after tg treatment. This difference in the magnitude of response to
thapsigargin between HapA and HapB echoes the findings in β-lymphocytes discussed
above. Interestingly, MEFs expressing the single amino-acid variant PERK constructs
may have an “intermediate” effect on thapsigargin response—this is suggested by ATF4
levels quantified in Figure 8. Note that ATF is highest for HapB +tg, followed by 136C
+tg and then 166Q +tg. This dampening of the effect of HapB in the single amino acid
variant constructs may indicate that these protein coding variations act synergistically to
change PERK’s biological activity. However, as these results were not statistically
significant, further study is needed (perhaps in a less variable model) to confirm this
finding. Additionally, further work should examine the effect on PERK function of
pseudophosphorylation at position 136 and position 704 (see PERK construct creation
breakdown under “PERK variant comparison in P-/- MEFs” above). Another PERK
construct that would be valuable in this future analysis is a 136A variant—this construct
would negate possible modifications at that site present in HapA (potential S136
phosphorylation) and HapB (potential disulfide bond formation at 136C).
Further study of PERK variants and both their differences in activity and their
effect on disease pathogenesis and progression seems warranted. Our previous work
demonstrated that PERK HapB is associated with risk for PSP, a neurodegenerative
disease. This work also showed that PERK is activated in post-mortem brain regions
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affected by PSP and Alzheimer’s disease. Other studies have shown PERK activation in
the brain in Parkinson’s disease (Hoozemans et al. 2007), ALS (Atkin et al. 2001, Wang
et al. 2010), AD (Hoozemans et al 2009), multiple system atrophy (Makioka et al. 2010)
and other tauopathies (Nijholt et al. 2012). Therefore, it may be that differences in PERK
function are magnified in the brain or that neurons are more sensitive to these
differences.
Further study into functional variations of PERK should also examine how posttranslational modifications affect differences in activity between HapA and HapB. HapA
contains two serines (S136 and S704) not present in HapB. Phosphorylation at either of
these sites could potentially affect activity. Thus, future studies could incorporate PERK
constructs pseudophosphorylated at these sites (136E and 704E). Conversely, this work
could also examine activity of PERK that is unphosphorylatable and incapable of
disulfide bonding at residue 136 (136A). Another way to approach this question would be
to determine by mass spectrometry whether either of these serines are phosphorylated
on endogenously expressed HapA PERK, either at baseline or in response to stress.
It may be that PERK -/- MEFs are not an ideal model to study PERK variation
and its contribution to disease pathogenesis. Because PERK plays a role in
neurodegeneration, future work could benefit from using neuronal cultures to explore this
question. The specialized functions of neurons and their heavy reliance on protein
translation may make them especially vulnerable to sustained PERK activation. Though
there are, as of yet, no neuronal cell culture models of tau aggregation (Guo & Lee,
2014), this type of system would be ideal for studying the interaction between PERK
variation and tau pathogenesis.
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Table 3.1 Primers for Site-Directed Mutagenesis
Primer Name

Primer Sequence (5' to 3')

166Q: g497a

5'-ctcttccagtgggaccaagaccgtgaaagcatg-3'

136C: c407g

5'-atgtgggatccggttgcttggtgtcatccag-3'

704A: t2110g_antisense

5'-gatttcaatatgttcttttgtagcgaaaggatccattctgcgtatt-3'

136C: c407g_antisense

5'-ctggatgacaccaagcaaccggatcccacat-3'

704A: t2110g

5'-aatacgcagaatggatcctttcgctacaaaagaacatattgaaatc-3'

166Q: g497a_antisense

5'-catgctttcacggtcttggtcccactggaagag-3'

Additional Primers: Phosphomimetic
t406g_c407a_c408g

5'-atttggatgtgggatccggtgagttggtgtcatccagccttag-3'

t2110g_c2111a_t2112g

5'cagttaaaatacgcagaatggatcctttcgagacaaaagaacatattgaaat
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catagctc-3'

t406g_c407a_c408g_antisense

5'-ctaaggctggatgacaccaactcaccggatcccacatccaaat-3'

t2110g_c2111a_t2112g_antisense

5'gagctatgatttcaatatgttcttttgtctcgaaaggatccattctgcgtattttaact
g-3'

Table 3.2 PERK Constructs
Construct Name
PERK Haplotype A
PERK Haplotype B
PERK 136C
PERK 166Q
PERK 704A
PERK 136E (phospho-mimetic)
PERK 704E (phospho-mimetic)

Amino Acid at position
136-166-704
S136-R166-S704
C136-Q166-A704
C136-R166-S704
S136-Q166-S704
S136-R166-A704
E136-R166-S704
S136-R166-E704

Table 3.3 Antibodies
Antibody Name
PERK C33E10
pPERK
eIF2α L57A5
peIF2α S51
ATF4 (Creb-2) SC-200
β-actin

Company
Cell Signaling Technologies
Eli Lilly
Cell Signaling Technologies
Cell Signaling Technologies
Santa Cruz
Cell Signaling Technologies
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Dilution
1:500
1:1000
1:1000
1:250
1:1000
1:50,000

Origin
Rabbit
Rabbit
Mouse
Rabbit
Rabbit
Mouse

A

B
A

R166Q

S704A

S136C

Figure 3.1. PERK construct vector map and schematic. A. Human PERK cDNA
clones were obtained from Transomic Technologies (Huntsville, AL; vector: pTCN;
image obtained from www.transomic.com). B. To create PERK variants, we
performed site-directed mutagenesis using the QuikChange Multi kit (Agilent
Technologies, Santa Clara, CA) at three sites: rs867529 (S136C), rs13045 (R166Q),
and rs1805165 (S704A). Together, these three variations make up “Haplotype B”
(HapB). We mutated PERK at all three HapB sites individually to determine whether
single amino acid variations affect PERK function. For a full list of PERK variant
constructs, see Table 3.2. SNP rs7571971, shown here in red, is associated with
PSP risk (REF) and is in LD with all three HapB SNPs.
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Relative density

A

B

Figure 3.2. Thapsigargin treatment time course for peIF2α. A. Western blot bands of
total eIF2α and peIF2α from PERK null MEFs expressing PERK HapA construct (Table
3.2). Phosphorylation of eIF2α peaked at 75 min/tg treatment. B. Quantification of
Western blots in A. Relative density for each peIF2α band normalized to corresponding
total eIF2α band.
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Figure 3.3. Relative quantification of PERK expression by qPCR. Each PERK
construct (B: HapB, A: HapA, 136: 136C, 166: 166Q, 704: 704A, pCTN: empty vector;
see Table 3.2) demonstrated less than twofold change in expression (relative
quantification score [RQ] of greater than 2 or less than 0.5). PERK constructs were
transfected into PERK null (-/-) MEFs and RNA harvested 24 hours later. PERK
expression detected by Taqman Gene Expression Assays (Life Technologies) designed
to detect PERK transcripts (PERK 1 and PERK 2). Endogenous control: HPRT1.
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Figure 3.4. Human β-lymphocytes endogenously expressing PERK haplotype A
and PERK haplotype B. A. Western blots comparing levels of total PERK, pPERK,
peIF2α, and total eIF2α between HapA and HapB, with and without 0.1μM tg treatment
(30min). Band quantifications were normalized to fast greenCell lines expressing PERK
haplotype A were NA06985, NA06991, NA06993, NA07029 (lanes 1-4 and 9-12,
respectively; cell lines expressing PERK haplotype B were NA07348, NA07357,
NA10835, NA11993 (lanes 5-8 and 13-16, respectively). Each lane represents one cell
line homozygous for HapA (n=4) or HapB (n=4). Loading controls: fast green and βactin. B-D. Quantification of Western blots in A. B. PERK levels did not vary significantly
between haplotypes or with drug treatment. C. peIF2α levels were significantly higher in
HapB cells after tg treatment. D. pPERK levels were significantly lower in HapB cells
with or without tg treatment. *p<0.05. Error bars represent standard deviation.

68

A

B

Figure 3.5 Western blots of PERK -/- MEFS expressing human PERK constructs.
A. Western blot loaded for visual comparison between constructs. B. Western blot
loaded for visual comparison between each construct with and without tg treatment. P-/=PERK null MEFs, pTCN=empty vector. For quantification, see Fig 3.6-3.9.
69

B

A

P E R K + tg

PERK
2 .0

* p=.05

r e la tiv e d e n s ity

r e la tiv e d e n s ity

2 .0

1 .5

1 .0

* p=.02

1 .5

1 .0

0 .5

0 .5

tg
+

tg
7

0

4

A

+
Q
6
6
1

3
1

p
a
H

6

B

C

+

+

tg

tg
+
p
a
H

7

1

A

A
4
0

6
6

3
1

a
H

Q

C
6

B
p

A
p
a
H

P E R K v a r ia n t

C

tg

0 .0

0 .0

P E R K v a r ia n t

PERK Tg
2 .0

r e la tiv e d e n s ity

U n tre a te d
+ th a p s ig a rg in
1 .5

1 .0

0 .5

A
4
0
7

1

6

6

Q

C
1

3

6

B
p
a
H

H

a

p

A

0 .0

P E R K v a r ia n t

Figure 3.6 Quantification of PERK from Western blots. A-B. Comparison of PERK
levels between constructs. P-values are comparisons between each construct and
HapA. A. PERK levels were not statistically different between constructs in the absence
of tg treatment. B. Tg treatment resulted in a dip in total PERK levels in HapB (p=0.02)
and 136C (p=.05) in comparison to HapA. C. Comparison of PERK levels with and
without tg treatment for each construct. P-values are comparisons within each construct
with and without tg. PERK levels did not significantly change within each construct with
tg treatment. All PERK bands normalized to fast green protein bands (loading control).
Error bars represent standard deviation.
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Figure 3.7 Quantification of pPERK from Western blots. A-B. Comparison of pPERK
levels between constructs. P-values are comparisons between each construct and
HapA. A. pPERK levels were not statistically different between constructs in the absence
of tg treatment. B. pPERK levels were significantly lower in 704A relative to HapA
(p=.01). C. Comparison of pPERK levels with and without tg treatment for each
construct. P-values are comparisons within each construct with and without tg. pPERK
for all constructs increased significantly with tg treatment (all p-values < 0.05). D. The
ratio of tg treated to untreated for each construct was not significantly different from the
tg treated to untreated for HapA, though tg treatment tended to have a greater
magnitude of effect on HapB. Error bars represent standard deviation.
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Figure 3.8 Quantification of peIF2α from Western blots. A-B. Comparison of peIF2α
levels between constructs. P-values are comparisons between each construct and
HapA. A. peIF2α levels were not statistically different between constructs with or B.
without tg treatment. C. Comparison of peIF2α levels with and without tg treatment for
each construct. P-values are comparisons within each construct with and without tg.
peIF2α for all constructs did not increase significantly with tg treatment (all p-values >
0.05). D. The ratio of tg treated to untreated for each construct was not significantly
different from the tg treated to untreated for HapA. Error bars represent standard
deviation.
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Figure 3.9 Quantification of ATF4 from Western blots. A-B. Comparison of ATF4
levels between constructs. P-values are comparisons between each construct and
HapA. A. ATF4 levels were not statistically different between constructs with or B.
without tg treatment. C. Comparison of ATF4 levels with and without tg treatment for
each construct. P-values are comparisons within each construct with and without tg.
ATF4 for all constructs did not increase significantly with tg treatment (all p-values >
0.05). D. The ratio of tg treated to untreated for each construct was not significantly
different from the tg treated to untreated for HapA. Error bars represent standard
deviation.
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Figure 3.10. Additional Western blot included in preceding analysis. P-/-=PERK null
MEFs, pTCN=empty vector. For quantification, see Figures 3.6-3.9.
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CHAPTER 4: GENERAL CONCLUSIONS AND FUTURE DIRECTIONS
Neurodegenerative diseases represent a major health crisis in the United States
and around the world. By the year 2050, an estimated 16 million older Americans will
suffer from Alzheimer’s disease (AD) at a cost of 1.2 trillion dollars in direct care
(Alzheimer’s Association, www.alz.org). Finding treatments that halt or delay disease
progression will be a major public health priority in the years to come. Because parts of
AD pathology overlap with the pathology of other age-related neurodegenerative
diseases, this push to discover and implement effective therapy may result in treatment
options for a number of other disorders, including the tauopathy progressive
supranuclear palsy (PSP). Likewise, research into the pathogenesis of PSP could have
implications for treating AD and other tauopathies.
Close examination of genetic risk factors for neurodegenerative disease is one
way to identify important pathogenic disease pathways and discover new inroads to
potential therapies. Large-scale genome-wide association screens (GWAS) and, more
recently, whole exome sequencing studies have provided researchers with a wealth of
information about potential contributors to neurodegenerative disease pathogenesis
(Desikan et al., 2015; Höglinger et al., 2011; Jun et al., 2015; Lambert et al., 2013; Naj et
al., 2011). Risk genes identified by SNP genotyping serve as “signposts” of risk—a
genome-wide significant SNP may not be the risk-conferring variant in and of itself.
Rather, the “hit” SNP is likely in high linkage disequilibrium (LD) with the true genetic
source of increased disease risk. The previous chapters detail and explore in-depth one
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example of this: the PSP risk gene EIF2AK3, which codes for the PERK protein. Though
the GWAS signal from EIF2AK3 came from an intronic SNP (rs7571971), that SNP was
in near complete LD with three SNPs that alter PERK protein coding (rs867529,
rs13045, and rs1805165). These PERK coding variants are functionally different from
one another (Liu et al., 2012) and are likely to be the source of increased PSP risk from
EIF2AK3.
PERK activation in neurodegenerative disease
Chapter 2 of this dissertation provides biological evidence that PERK is
associated with tau pathology in the brain. In a comparison of post-mortem brain tissue
from PSP, AD and normal controls, the greatest number of phosphorylated PERKpositive cells were in brain regions highly affected in each disease. pPERK and peiF2α
were highest in the brainstem in PSP and in the hippocampus in AD. This puts PERK “at
the scene of the crime” not only in PSP, but also in AD and in some elderly controls
(Stutzbach et al., 2013). This also confirms and expands upon similar findings from other
groups (J J M Hoozemans et al., 2007; Jeroen J M Hoozemans et al., 2009; D. a T.
Nijholt et al., 2011). pPERK postitive cells also tended to be positive for htau, especially
diffuse htau. This suggests that PERK activation precedes formation of neurofibrillary
tangles (NFTs) and thus may be an early event in disease pathogenesis. This, too,
reinforces findings from other groups (Jeroen J M Hoozemans et al., 2009).
Intriguingly, some elderly controls exhibited moderate pPERK staining in the
hippocampus. A correlation analysis demonstrated that PERK activation increased with
both age and tau pathology. This novel finding suggests that PERK activation and tau
both tend to increase in the aging brain. Whether PERK and tau directly influence one
another is a question for future study. PERK may affect tau pathology in one or more
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steps of the pathogenic process: 1.) PERK could influence whether a cell forms
aggregates, either at the point of protein delivery to the cytoplasm or at the point of
aggregation and/or 2.) PERK could influence downstream effects of tau aggregation.
The UPR and tau intersect in several protein degradation pathways, including the
proteasome system (Yen, 2011), which is the target of the ERAD pathway (Travers et
al., 2000), and the endosome to lysosome pathway (Guo & Lee, 2011).
Another finding that could account for the connection between PERK variation
and tauopathy is the association of tau with the rough endoplasmic reticulum (Iqbal et
al., 2009). Recent work demonstrated that abnormally phosphorylated tau partially
colocalized with several subcellular compartments, including the ER (Tang et al., 2015).
This colocalization would bring tau aggregates and the UPR machinery in close
proximity, providing an opportunity for these two processes to interact more directly with
one another.
One cell culture model that could be useful to investigating this question was
established by the Lee group at University of Pennsylvania (Guo & Lee, 2011). Guo and
Lee (2011) transduced pre-formed tau fibrils (pffs) into QBI-293 cells expressing
exogenous tau. This transduction resulted in formation of NFT-like tau aggregates within
a matter of hours. Strikingly, incubating these same tau-expressing cells in media
containing tau pffs resulted in spontaneous endocytosis-mediated uptake of these
protein seeds and subsequent tangle formation, even in the absence of a protein
delivery reagent. This model is thus useful for studying intracellular tau aggregation,
abnormal tau degradation, and/or tangle-induced toxicity in cell culture and also could
provide insight into cellular processes that affect uptake of abnormal tau and delivery to
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the cytoplasm. Other potentially useful cell culture models of tau aggregation use
fluorescently tagged tau to monitor aggregation in real time (reviewed in Lim et al. 2014)
and may bypass some of the experimental drawbacks of post-fixation examination of tau
aggregation.
Using one of these cell culture models of tau aggregation, future work could
examine 1) whether/when PERK is activated during the uptake, seeding, or aggregation
process and 2) whether perturbing PERK affects tau uptake, seeding, or aggregation.
PERK could be manipulated in several ways: 1) Gross pharmacological induction of the
UPR via thapsigargin (Rogers et al., 1995) or tunicamycin (Elbein, 1987) 2) specific
pharmacological prolongation of eIF2α phosphorylation via salubrinal (Boyce et al.,
2005) 3) expression and activation of a stress-independent, drug-inducible PERK
construct (Fv2E-PERK; Lu et al., 2004) 4) PERK knockdown via RNAi 5) PERK
inhibition via treatment with GSK2656157 (Atkins et al., 2013) or 6) expression of the
PERK variant constructs detailed in Chapter 3 of this dissertation.
PERK variation and its effect on PERK function
Chapter 2 also presents data supporting the hypothesis that a three amino acid
coding variant haplotype of the PERK protein, HapB, contributes to PSP risk (Stutzbach
et al., 2013). HapB PERK induces higher levels of eIF2α phosphorylation in response to
thapsigargin treatment than does HapA PERK (Liu et al., 2012). Because the higher
activity HapB PERK is also higher risk for PSP, it follows that this increased activity is
not adaptive and may actually be pathogenic. One explanation for this could be that
prolonged phosphorylation of eIF2α damages the neuron via extended translational
inhibition (Moreno et al., 2012). Continual synthesis of new proteins and
neurotransmitters are essential to neuronal function in general and memory formation in
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particular. Long-term potentiation (LTP), an important component of memory formation
at the cellular level, is inhibited by eIF2α phosphorylation (Ma et al., 2013), and an overactive eIF2α kinase could disrupt this important process.
Thus, though PERK activation in the short-term and in moderation may be
adaptive, extended PERK activity may irreparably damage a neuron. Even a modest
increase in PERK activity might bias a cell toward dysfunction, especially as pathological
protein aggregates accumulate in the cytoplasm and challenge homeostasis in myriad
ways. It could be that as we age, our neurons are more vulnerable to these stressors as
more pathological proteins accumulate, increasing the likelihood of cell death in
response to a challenge.
Chapter 3 explores the origin of this differential eIF2α kinase activity between
HapA and HapB. HapB is composed of the following three amino acid variations:
Ser136Cys, Arg166Gln, and Ser704Ala. Amino acids 136 and 166 are located on the
luminal, dimerization end of the PERK protein; amino acid 704 is on the cytoplasmic,
kinase-domain side of the protein. Though all three coding variants are usually inherited
together (Liu et al., 2012; Stutzbach et al., 2013), it is possible that only one of the
changes is responsible for the difference in activity between the two versions of the
PERK protein.
This work explores this possibility in two ways. First, data from Chapter 3
replicated the finding from Liu et al. (2012) that HapB PERK phosphorylates more eIF2α
in response to thapsigargin treatment than does HapA. Seemingly in contrast, HapB βlymphocytes also showed relatively less PERK phosphorylation in response to this same
drug treatment. If this effect is not due to a difference in pPERK antibody affinity
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between the haplotypes, it could indicate that HapB is actually less likely to
transautophosphorylate and more likely to phosphorylate eIF2α. Future work should
explore this possibility.
Expressing artificial PERK variants with these individual amino acid changes in
PERK null mouse embryonic fibroblasts (MEFs) did not yield significant differences in
PERK activity. However, these results suggest a trend toward HapB-expressing cells
having a stronger response to tg treatment. HapB expressing cells showed a bigger
difference between baseline levels of pPERK, peIF2α, and ATF4 and these same levels
after tg treatment. This difference in the magnitude of response to thapsigargin between
HapA and HapB echoes the findings in β-lymphocytes discussed above. Interestingly,
MEFs expressing the single amino-acid variant PERK constructs may have an
“intermediate” effect on thapsigargin response, though the current data are only
preliminary given the lack of statistical significance.
Further study into functional variations of PERK should also examine how posttranslational modifications affect differences in activity between HapA and HapB. HapA
contains two serines (S136 and S704) not present in HapB. Phosphorylation at either of
these sites could potentially affect activity. Thus, future studies could incorporate PERK
constructs pseudophosphorylated at these sites (136E and 704E). Conversely, this work
could also examine activity of PERK that is unphosphorylatable and incapable of
disulfide bonding at residue 136 (136A). Another way to approach this question would be
to determine by mass spectrometry whether either of these serines are phosphorylated
on endogenously expressed HapA PERK, either at baseline or in response to stress.
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It may be that PERK -/- MEFs are not an ideal model to study PERK variation
and its contribution to disease pathogenesis. Because PERK plays a role in
neurodegeneration, future work could benefit from using neuronal cultures to explore this
question. The specialized functions of neurons and their heavy reliance on protein
translation may make them especially vulnerable to sustained PERK activation. Though
there are, as of yet, no neuronal cell culture models of tau aggregation (Guo & Lee,
2014), this type of system would be ideal for studying the interaction between PERK
variation and tau pathogenesis.
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